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Abstract
Th e human gastrointestinal (GI) microbiota is a complex ecosystem that lives in sym-
biosis with its host. Th e growing awareness of the importance of the microbiota to the 
host as well as the development of culture-free laboratory techniques and computational 
methods has enormously expanded our knowledge of this microbial community. Irri-
table bowel syndrome (IBS) is a common functional bowel disorder aff ecting up to a fi ft h 
of the Western population. To date, IBS diagnosis has been based on GI symptoms and 
the exclusion of organic diseases. Th e GI microbiota has been found to be altered in this 
syndrome and probiotics can alleviate the symptoms, although clear links between the 
symptoms and the microbiota have not been demonstrated. Th e aim of the present work 
was to characterise IBS related alterations in the intestinal microbiota, their relation to 
IBS symptoms and their responsiveness to probiotic theraphy.
In this thesis research, the healthy human microbiota was characterised by cloning and 
sequencing 16S rRNA genes from a faecal microbial community DNA pool that was fi rst 
profi led and fractionated according to its guanine and cytosine content (%G+C). Th e 
most noticeable fi nding was that the high G+C Gram-positive bacteria (the phylum Acti-
nobacteria) were more abundant compared to a corresponding library constructed from 
the unfractionated DNA pool sample. Previous molecular analyses of the gut micro-
biota have also shown comparatively low amounts of high G+C bacteria. Furthermore, 
the %G+C profi ling approach was applied to a sample constructed of faecal DNA from 
diarrhea-predominant IBS (IBS-D) subjects. Th e phylogenetic microbial community 
comparison performed for healthy and IBS-D sequence libraries revealed that the IBS-D 
sample was rich in representatives of the phyla Firmicutes and Proteobacteria whereas 
Actinobacteria and Bacteroidetes were abundant in the healthy subjects. Th e family Lach-
nospiraceae within the Firmicutes was especially prevalent in the IBS-D sample.
Moreover, associations of the GI microbiota with intestinal symptoms and the quality 
of life (QOL) were investigated, as well as the eff ect of probiotics on these factors. Th e 
microbial targets that were analysed with the quantitative real-time polymerase chain 
reaction (qPCR) in this study were phylotypes (species definition according to 16S 
rRNA gene sequence similarity) previously associated with either health or IBS. With a 
set of samples, the presence or abundance of a phylotype that had 94% 16S rRNA gene 
sequence similarity to Ruminococcus torques (R. torques 94%) was shown to be associated 
with the severity of IBS symptoms. Th e qPCR analyses for selected phylotypes were also 
applied to samples from a six-month probiotic intervention with a mixture of Lactobacil-
lus rhamnosus GG, L. rhamnosus Lc705, Propionibacterium freudenreichii ssp. shermanii 
JS and Bifi dobacterium breve Bb99. Th e intervention had been previously reported to 
alleviate IBS symptoms, but no associations with the analysed microbiota representatives 
were shown. However, with the phylotype-specifi c assays applied here, the abundance of 
the R. torques 94% -phylotype was shown to be lowered in the probiotic-receiving group 
during the probiotic supplementation, whereas a Clostridium thermosuccinogenes 85% 
phylotype, previously associated with a healthy microbiota, was found to be increased 
compared to the placebo group.
To conclude, with the combination of methods applied, higher abundance of Actino-
bacteria was detected in the healthy gut than found in previous studies, and signifi cant 
phylum-level microbiota alterations could be shown in IBS-D. Th us, the results of this 
study provide a detailed overview of the human GI microbiota in healthy subjects and in 
subjects with IBS. Furthermore, the IBS symptoms were linked to a particular clostridial 
phylotype, and probiotic supplementation was demonstrated to alter the GI microbiota 
towards a healthier state with regard to this and an additional bacterial phylotype. For 
the fi rst time, distinct phylotype-level alterations in the microbiota were linked to IBS 
symptoms and shown to respond to probiotic therapy.
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Immediately aft er birth, microbes start to col-
onise the human gastrointestinal (GI) tract, 
followed by a lifelong symbiosis with the host 
(Camp et al., 2009). As a result, the adult GI 
microbiota forms a taxonomically complex 
and ecologically dynamic ecosystem with 
up to 1014 microbes in total, the main phyla 
in colon being low %G+C Gram-positive 
Firmicutes, high %G+C Gram-positive Acti-
nobacteria and Gram-negative Bacteroidetes 
and Proteobacteria (Andersson et al., 2008; 
Turnbaugh et al., 2009). Most of the bacteria 
present are strict anaerobes, which are diffi  cult 
to culture, and the approaches to study the 
diversity of this community are thus culture-
free (Zoetendal et al., 2008). As the GI tract is 
exposed to this vast number of microbes, dis-
turbances in the microbiota aff ect individual 
health, and vice versa (Sekirov et al., 2010).
Up to a fi ft h of the Western population 
suff ers from irritable bowel syndrome (IBS), 
which is a functional bowel disorder that 
impairs the quality of life (QOL) (Longstreth 
et al., 2006). Th e term IBS refers to the symp-
toms, which include pain or discomfort asso-
ciated with alterations in bowel habits (Long-
streth et al., 2006). Multifactorial aetiologies 
have been proposed for the syndrome, altered 
gut microbiota being one of these factors 
(Malinen et al., 2005). Probiotics have shown 
a beneficial effect in many gastrointestinal 
conditions, including IBS, and the alleviation 
of IBS symptoms has been demonstrated with 
many probiotic strains and mixtures (Spiller, 
2008).
In the research of this thesis, the GI 
microbiota of control subjects devoid of 
GI symptoms and patients with diarrhea-
predominant IBS (IBS-D) was investigated 
by applying a method that enabled the seg-
regation of the microbial community DNA 
according to its genomic %G+C content, fol-
lowed by a sequencing approach to charac-
terise the IBS-D-associated microbiota. Th e 
associations between intestinal symptoms 
and GI microbiota in IBS and samples from 
a six-month probiotic intervention trial were 
also assessed. Th e GI mirobiota analyses were 
conducted by using phylotype (species defi ni-
tion according to 16S rRNA gene sequence 
similarity) specifi c quantitative real-time PCR 




2. REVIEW OF THE LITERATURE
2.1  Gastrointes  nal (GI) 
microbiota
2.1.1  Development of the GI 
microbiota
From birth onwards, a complex microbiota 
begins to colonise the human GI tract (Favier 
et al., 2002; Koenig et al., 2011) (Figure 1). 
Th e microbiota remains dynamic and resilient 
throughout adulthood (Biagi et al., 2010). Th e 
delivery mode is crucial, as babies born by 
Caesarean section have a diff erent colonisa-
tion pattern from those delivered through the 
birth canal (Dominguez-Bello et al., 2010). 
Th e next main environmental factor aff ecting 
the colonisation pattern is the diet, as babies 
fed breast milk babies have a diff erent species 
profi le within their GI microbiota compared 
to formula-fed babies (Roger & McCartney, 
2010). Delivery via the birth canal and breast 
feeding are both associated with higher counts 
and more diverse populations of bifi dobacte-
ria (Favier et al., 2002; Eggesbø et al., 2011). 
Th e GI microbiota enters a third funda-
mental modification stage during weaning 
(Kurokawa et al., 2007), and typically by one 
year of age it reaches a more stable and diverse 
stage (Palmer et al., 2007). High subject 
specifi city and relative stability over time are 
characteristic of the GI microbiota through 
adulthood (Vanhoutte et al., 2004; Rajilić-
Stojanović et al., 2009). In the elderly, the 
microbiota becomes less diverse (Enck et al., 
2009b; Rajilić-Stojanović et al., 2009; Claes-
son et al., 2010). Eventually, the microbiota 
becomes signifi cantly altered in centenarians 
(Biagi et al., 2010). In addition, the genotype 
(Turnbaugh et al., 2009) as well as environ-
mental factors such as geographical origin (Li 
et al., 2008), diet (Muegge et al., 2011), weight 
(Turnbaugh et al., 2009), health status (Seki-
rov et al., 2010), antimicrobial medication 
(Jakobsson et al., 2010), and the consumption 
of probiotics (Kajander et al., 2008) and pre-
biotics (Flint et al., 2007) may aff ect the com-
position of the GI microbiota throughout life.
2.1.2  Ecology and composi  on of 
the GI microbiota
Th e luminal content and mucosal surface of 
the human GI tract harbour highly diverse 
and dense bacterial ecosystems (Eckburg et 
al., 2005) (Figure 1). Distinct longitudinal 
variation exists in the composition of the GI 
microbiota within the 7-m-long GI tract, as 
the diversity and quantity of bacteria rises 
along diff erent parts of the intestine towards 
the rectum, where the density reaches approx-
imately 1012 cfu per 1g of faeces. Th e content 
of the GI canal undergoes continuous succes-
sion, as the bacteria are supplied with nutri-
ents from food and peristalsis moves the 
colonic content, lubricated by mucus. Th ere 
is also a fl ow of liquids and salts, and the pH 
gradually rises along the intestine from low to 
neutral (Duncan et al., 2009). Th e daily load 
of liquids to the small intestine is approxi-
mately nine litres, seven litres of which con-
sist of secretions and two litres comes from 
the dietary intake (Surawicz, 2010). Th e small 
intestine absorbs seven litres of this liquid and 
the colon absorbs the rest (Surawicz, 2010). 
Th e GI tract is highly folded, with crypts and 
villi within the mucosal surface, adding up 
to a surface area of 200-400 m2. Latitudinal 
variation in the composition of the GI micro-
biota can be found within each intestinal sec-
tion, as the luminal and mucosal (Zoetendal 
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et al., 2002; Kerckhoff s et al., 2010) and the 
liquid- and particle-associated microbiotas 
are distinct (Walker et al., 2008). Th e viscous 
mucus consists of two layers: a sterile, thinner 
inner layer and a thicker outer mucus layer 
occupied by bacteria (Johansson et al., 2008; 
Johansson et al., 2011).
All three domains of life, Bacteria, 
Archaea and Eukaryotes, exist in the intestine, 
as well as many viruses (Rajilić-Stojanović et 
al., 2007; Reyes et al., 2010). Th e representa-
tion of Arhaea is dominated by one species, 
Methanobrevibacter smithii (Eckburg et al., 
2005). Th e predominant bacterial phyla in the 
GI tract are low G+C Gram-positive Firmi-
cutes, high G+C Gram-positive Actinobacteria 
and Gram-negative Bacteroidetes and Proteo-
bacteria (Figure 1). Other less prevalent phyla 
include Verrucomicrobia, Fusobacteria and 
Cyanobacteria (Rajilić-Stojanović et al., 2007). 
Th e majority of the bacterial species encoun-
tered in the GI tract are strictly anaerobic and 
have no cultured representatives. Th us, knowl-
edge of their existence is based on sequencing 
of intestinal community samples (see section 
2.2.2). Up to over a thousand bacterial species 
are estimated to be present in an individual’s 
microbiota (Rajilić-Stojanović et al., 2007; Tap 
et al., 2009; Qin et al., 2010). In total the bac-
terial species associated with the human GI 
tract have been approximated to include from 
fi ve to tens of thousands of species, depend-
ing of the methodology used (Frank et al., 
2007; Zoetendal et al., 2008). Some bacteria 
are transient, some colonise the GI tract tem-
porarily and some are commensals, together 
forming an equilibrium. It is not clear whether 
the presence, abundance or proportion of cer-
tain bacteria is signifi cant to the host. It has 
been suggested that a dominant and prevalent 
set of largely shared microbes, referred to as 
the common core GI microbiota, is present 
in the gut of humans. However, the defini-
tion of the core GI microbiota is under debate 
(Rajilić-Stojanović et al., 2009; Tap et al., 
2009; Qin et al., 2010; Jalanka-Tuovinen et al., 
2011). Very recently, the human gut micro-
biota has been divided into three main entero-
types dominated by Bacteroides, Prevotella or 
Ruminococcus (Arumugam et al., 2011).
2.1.3  Role of the GI microbiota
Th e GI microbiota co-evolves with the host, 
functioning as an organ within an organ 
(Camp et al., 2009). The human host is a 
stable environment supplying nutrients to 
the microbes, while the microbes have an 
impact on the host mucosa (Leser & Mølbak, 
2009). Th e gut microbiota forms a function-
ally uniform ecosystem among human adults 
(Kurokawa et al., 2007; Turnbaugh et al., 
2009; Gosalbes et al., 2011), and the collec-
tive microbial genomes in the GI tract encode 
capabilities lacking from our own genomes 
(Camp et al., 2009). Dietary carbohydrates are 
converted to hydrogen, carbon dioxide, meth-
ane and short-chain fatty acids (SCFA) (ace-
tate, probionate, butyrate), of which butyrate 
is the main energy source for gut epithelial 
cells (Guarner, 2006). Th e butyrate producers 
are mainly Firmicutes, including members of 
Clostridium clusters XIV and IV (Collins et 
al., 1994), and are highly abundant in the gut 
(Louis et al., 2010). Th e degradation of pro-
teins produces not only SCFAs but also poten-
tially toxic substances. The GI microbiota, 
however, transforms many potential carcino-
gens and activates bioactive compounds, pro-
duces essential vitamins (such as K, B12 and 
biotin), contributes to bile acid metabolism 
and recirculation, aff ects to the absorption of 
calcium, magnesium and iron, and partici-
pates in the regulation of fat storage (Guarner, 
2006; Leser & Mølbak, 2009). Furthermore, 
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Figure 1. Characteristics of the human GI tract and microbiota (Pei et al., 2004; Aas et al., 2005; 
Bik et al., 2006; Dethlefsen et al., 2006; Booijink et al., 2007; Tap et al., 2009; Booijink et al., 2010; 
Sekirov et al., 2010).
1-2 years
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the GI microbiota participates in the matu-
ration of the host immune system and in 
homeostasis (Round & Mazmanian, 2009). 
Th e GI microbiota has protective functions, as 
it acts as a barrier and protects the host from 
pathogens, a function referred to as colonisa-
tion resistance (Stecher & Hardt, 2008).
2.1.4  Health-related disturbances 
in the GI microbiota
 As the GI tract is the body’s largest immu-
nological tissue and is exposed to a vast 
number of bacteria, disturbances in the GI 
microbiota are expected to be linked to many 
health problems, as reviewed by Sekirov et al. 
(2010) and Neish et al. (2009). The mecha-
nisms underlying such alterations or dysbiosis 
are still oft en unknown, and in many cases it 
remains unresolved whether changes in the 
GI microbiota are a primary or a secondary 
phenomenon. Moreover, multifactorial aeti-
ologies aff ect many health conditions, such as 
host susceptibility and other environmental 
factors besides GI microbes. According to the 
microfl ora hypothesis (Kirjavainen & Gibson, 
1999; Noverr & Huff nagle, 2005), which is an 
extension to the hygiene hypothesis (Strach-
an, 1989), the reduced or aberrant microbial 
exposure results in a cascade of underdevel-
oped microbiota, immature immunological 
tolerance and an increased incidence of aller-
gy. Antimicrobial agents not only aff ect the 
pathogens against which they are directed, but 
may also have impact on other members of 
the intestinal microbiota. Antibiotics reduce 
the diversity of the gut microbiota and can 
have long-lasting or even permanent eff ects 
on the microbial composition (Jernberg et al., 
2007; Dethlefsen et al., 2008; Jakobsson et al., 
2010). Acute effects of antibiotic treatment 
include diarrhoea, whereas long-term conse-
quences are more diffi  cult to perceive. Allergic 
disease and autism are chronic conditions that 
have been associated with frequent antibiotic 
use in childhood (Song et al., 2004; Risnes et 
al., 2011). Diseases aff ecting systemic health, 
inflammatory bowel disease (IBD) and GI 
tract cancers are among the conditions asso-
ciated with alterations in the GI microbiota, 
with some confl icting results (Table 1).
2.2  Molecular methods applied 
in GI microbial community 
analysis
2.2.1 The 16S rRNA gene
Culture-independent methods have been 
widely used in research of the GI microbiota, 
as approximately of 50-90% of the microbes in 
the GI tract are currently unculturable (Zoe-
tendal et al., 2008). The methods are often 
based on detecting the gene coding for the 16S 
ribosomal ribonucleic acid (16S rRNA gene), 
which is a component of the 30S subunit of 
all prokaryotic ribosomes. As the 16S rRNA 
gene is functionally universal, sufficiently 
conserved, convenient in size (approximately 
1500 bp), and large sequence databases exist 
for comparison, it is the most oft en used phy-
logenetic marker (Woese, 1987). To date, the 
number of 16S rRNA gene sequences in gene 
data banks exceeds 1.5 million. Th e term ‘spe-
cies’ requires phenotypic characterisation of a 
bacterium and is inappropriate when the only 
available information is the 16S rRNA gene 
sequence. Th erefore, 16S rRNA gene sequenc-
es can be grouped according to their similarity 
in terms of operative taxonomic units (OTUs). 
A cut-off  value of 97-99% similarity between 
sequences within an OTU is often used to 
define a species representative, also termed 
a phylotype. The 16S rRNA gene contains 
conserved and variable regions that can be 
applied in detecting and identifying bacteria 
Review of the Literature
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Table 1. Th e microbiota associations in diff erent disease conditions. 






↓ Bifi dobacterium adolescentis
↓ Lactobacillus spp.
↓ Clostridium diffi  cile
↑ Clostridium spp.
↓ Bifi dobacterium spp.
↑ Escherichia coli 
↑ Clostridium diffi  cile
   (alterations in infancy)
Sjögren et al. 2009
Kalliomäki et al. 2001




Ley et al. 2006
Ley et al. 2006 and
Turnbaugh et al. 2009
Turnbaugh et al. 2009
Type 2 Diabetes ↓ Firmicutes
↓ class Clostridia
Larsen et al. 2010
Infl ammatory bowel disease
Ulcerative colitis ↓ Clostridium cluster XIV
↓ Firmicutes 
↓ Bacteroidetes 
Sokol et al. 2006
Frank et al. 2007 
Crohn’s disease ↓ Clostridium cluster IV
↓ Firmicutes
↓ Bacteroidetes






Sokol et al. 2006
Frank et al. 2007
Sokol et al. 2008
and Willing et al. 2009
Willing et al. 2009
Willing et.al. 2010
GI tract cancers
Gastric cancer ↑ Helicobacter pylori Correa et al. 2007
Colorectal cancer ↑ Clostridium spp.
↓ Collinsella aerofaciens 
Scanlan et al. 2008
Moore & Moore 1995
Other
Acute appendicitis ↑ Fusobacterium spp. Swidsinski et al. 2011
Autistic disorder ↑ Clostridium spp. Song et al. 2004 and
Parracho et al. 2005
Cholelithiasis ↑ Escherichia coli Abeysuriya et al. 2008
↑, increase relative to healthy subjects; ↓, decrease relative to healthy subjects.
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on diff erent taxonomic levels. However, one 
factor bringing inaccuracy to the quantifi ca-
tion of targeted phylotypes or bacterial groups 
is the varying copy number of the 16S rRNA 
gene per microbial genome (Farrelly et al., 
1995).
Each step in bacterial community analy-
sis is exposed to biases, starting from cell lysis 
and DNA extraction (Salonen et al., 2010b). 
The polymerase chain reaction (PCR) is 
involved in most of the culture-free assays for 
microbial community samples that detect the 
16S rRNA gene (Table 2). As the amplifi cation 
is exponential and as the microbial communi-
ty sample contains DNA from diff erent bacte-
ria in varying ratios, the product always con-
tains a biased quantity of amplicons favouring 
DNA from the dominant bacterial species. 
Furthermore, the amplifi cation of high %G+C 
bacteria is weaker than low %G+C bacteria 
(von Wintzingerode et al., 1997), even though 
the %G+C content of the 16S rRNA gene does 
not vary as much between the species as the 
genomic %G+C content (Haywood-Farmer & 
Otto, 2003). Th e secondary structures formed 
by the 16S rRNA loops can restrain the poly-
merase from proceeding in amplifi cation or 
the sequencing reaction (von Wintzingerode 
et al., 1997). The formation of chimeras, 
which are amplicons containing DNA from 
two or more species, can also occur in the 
amplifi cation reactions (von Wintzingerode et 
al., 1997). Furthermore, the primers are prone 
to annealing with diff ering effi  ciency depend-
ing on the nucleotide mismatches in the tem-
plate. Although the conserved domains of the 
16S rRNA gene off er primer sites for universal 
assay applications, no truly universal primers 
are available that would equally amplify all 
templates. Nevertheless, despite all the uncer-
tainty caused by the nature of the 16S rRNA 
gene and technical issues, community analy-
sis can oft en be considered as quantitative or 
semiquantitative, depending on the method 
applied (see section 2.2.1.1).
2.2.1.1 Applicable techniques
Th e most suitable methodology for GI com-
munity analysis depends on the research 
frame. An overview of the methods is provid-
ed in Table 2. Th e analyses applied in research 
on the GI microbiota in relation to IBS are 
presented in Table 3. Profi ling the microbial 
community according to the percentage of 
genomic guanine and cytosine (%G+C) is 
an example of a non-quantitative approach 
(Holben & Harris, 1995). Th is is oft en used in 
combination with other methods (Dicksved 
et al., 2008; Mäkivuokko et al., 2009). Finger-
printing methods such as denaturing gradient 
gel electrophoresis (DGGE), temperature gra-
dient gel electrophoresis (TGGE) and termi-
nal restriction fragment length polymorphism 
(T-RFLP) are considered as semiquantita-
tive methods that can be used in monitoring 
the GI microbiota in general or in focusing 
on specific groups of bacteria (Vanhoutte 
et al., 2004; Jernberg et al., 2007; Biasucci et 
al., 2010). Fluorescent in situ hybridisation 
(FISH) (Mueller et al., 2006) and phylogenetic 
microarray applications (Palmer et al., 2007; 
Rajilić-Stojanović et al., 2009; Saulnier et al., 
2011) are quantitative nucleotide probe-based 
methodologies applied to the GI microbiota. 
Quantitative real-time PCR is a rapid, sensi-
tive and highly quantitative analysis method 
capable of detecting and quantifying minor 
representatives in the gut microbiota, and it 
has therefore been used, for example, in the 
detection of pathogens and in the monitor-
ing of probiotic interventions (Malinen et 
al., 2003; Kajander et al., 2007; Rinttilä et al., 
2011). Primer- and probe-based methods do 
not necessarily detect novel phylotypes, since 
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Table 2. Key methods used to study the intestinal microbial community.
Technique Descrip  on Features
Culturing Growing of bacteria in unselective or 
selective media
• Most of the GI bacteria are uncultur-
able and thus not detected
• Provides bacterial isolates
DGGE and 
TGGE
Separation of the amplifi ed DNA bands 
in a denaturing or temperature gradi-
ent followed by  presence, absence and 
intensity analysis of  DNA bands
• Overview of the whole community
• Taxonomic level can be adjusted with 
primer selection
• Bands can be isolated for further 
identifi cation
• Reproducible
FISH Visualisation of intact cells • Dead and living cells can be separated
• Spatial detection of bacteria 
%G+C profi ling Genomic community DNA profi ling 
according to the G+C content 




Semiquantitative detection of target 
DNA by hybridisation
• High throughput
• Suitable for simultaneously monitor-
ing thousands of microbes in one 
analysis
qPCR Detection of the amplifi ed target DNA • Highly sensitive
• Quantitative
• High throughput
Sequencing Provision  of nucleotide-level informa-
tion on the sequenced amplicons
• Enables novel sequence detection
• Phylogenetic analysis possible
• Suitable for simultaneously monitor-
ing thousands of microbes in one 
analysis
T-RLFP Restriction digestion of amplicons 
providing a pattern of the terminal 
labelled fragments 
• Overview of the whole community
• Fast
DGGE, denaturing gradient gel electrophoresis; TGGE, temperature gradient gel electrophoresis; FISH, fl uo-
rescent in situ hybridisation; %G+C, percentage guanine plus cytosine; qPCR, quantitative real-time poly-
merase chain reaction; T-RFLP, terminal-restriction fragment length polymorphism.
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the design of primers and probes is depen-
dent on the available sequence data. Methods 
based on sequencing are ideal for mapping 
the diversity of the faecal microbiota and they 
supply sequence information for oligonucle-
otide and probe design.
Metagenomic approaches examine all 
genetic content in a community to observe the 
genetic potential and in addition provide phy-
logenetic information through the analysis of 
16S rRNA genes (Gill et al., 2006; Manichanh 
et al., 2006; Kurokawa et al., 2007; Qin et al., 
2010). Whole genome data-bases presently 
cover 396 resident GI tract bacteria (Septem-
ber 2011, http://www.hmpdacc-resources.org/
cgi-bin/img_hmp/main.cgi; Markowitz et al., 
2010), which can be used to annotate metage-
nomic sequence data. Microbial community 
analysis provides information on the microbes 
present in certain health conditions, but does 
not indicate whether the microbes are a result 
or a cause of the condition. Functions and 
host-microbe interactions can be investigat-
ed using bacterial isolates, animal models, in 
vitro models and diff erent -omics approaches, 
including proteomics, transcriptomics, metab-
olomics (Zoetendal et al., 2008; Hattori & Tay-
lor, 2009) and meta-transcriptomics (Gosalbes 
et al., 2011). 
2.2.2  Sequencing of the GI 
microbiota
The development of sequencing technolo-
gies and the application of microbial ecology 
statistics combined with computational tools 
have revolutionised the culture-independent 
approaches to microbial communities, includ-
ing the GI microbiota (Figure 2). Studies on 
the characterisation of the normal healthy fae-
cal microbiota with Sanger dideoxy sequenc-
ing of the 16S rRNA gene clone libraries start-
ed in the 1990´s and resulted in a few hundred 
Review of the Literature
sequences from a few individuals (Wilson & 
Blitchington, 1996). Th e estimated numbers 
of faecal bacterial phylotypes in individuals 
in these studies were some hundreds. Th e fi rst 
large-scale 16S rRNA gene study on the faecal 
microbiota based on Sanger dideoxy sequenc-
ing was published by Eckburg et al. (2005), 
and since then estimates have been around 
a thousand phylotypes in an individuals gut. 
Second-generation pyrosequencing methods 
made sequencing more effective and eco-
nomical and changed the proportions of phyla 
(Andersson et al., 2008).
Th e sequencing studies performed thus 
far to characterise the healthy human GI 
microbiota have analysed a combined total of 
only some hundreds of individuals represent-
ing a restricted range of nationalities (Figure 
2). Furthermore, the comparison of results 
from diff erent studies is problematic due to 
the considerable variation in methodological 
parameters, such as sample preparation, DNA 
extraction, primer and probe selection and 
the region of the 16S rRNA gene sequenced 
(Salonen et al., 2010b). The phylum-level 
deviation between these studies has also been 
broad. Th e development of third-generation 
sequencing techniques will facilitate even 
more extensive sequencing to explore the 
microbiota of greater number of individuals 
with better coverage (Eid et al., 2009).
2.2.2.1  Microbial community 
structure analysis
In culture-free microbial community analysis, 
a high sequence similarity in the 16S rRNA 
gene sequence forms a species-like concept 
referred to as phylotype or OTU. Statistical 
methods to assess the diversity and structure 
of the microbiota have been adapted from 
macroorganisms, and conclusions should be 
drawn considering the limitations introduced 
10
due to the prokaryotic nature of the sequence 
data. Several web applications have facilitated 
convenient analysis for affi  liating phylotypes 
and observing the phylogenetic structure of 
microbial communities (Schloss & Handels-
man, 2005; Schloss & Handelsman, 2006; Loz-
upone & Knight, 2008; Cole et al., 2009).
Th e coverage of sampling can be tested to 
monitor the depth of community sequencing. 
Th is can be calculated with Good’s formula 
[1-(n/N)] (Good, 1953), in which ‘N’ is the 
number of cloned sequences and ‘n’ represents 
the number of single-clone OTUs. Th e cumu-
lative number of phylotypes versus sequenced 
clones can be plotted as an accumulation 
curve. A curve that reaches the plateau indi-
cates a well sampled community (Hughes 
et al., 2001). In addition, rank-abundance 
curves can be drawn to visualise the com-
munity structure, in which the abundance of 
each phylotype is plotted against the species 
ordered from the most abundant to the least 
abundant (Hughes et al., 2001).
Diversity consists of species richness and 
evenness. High diversity is generally thought 
to be beneficial for an ecosystem due to its 
balancing effect on the structure of a com-
munity under stressful conditions. Diversity 
is oft en used as a term of richness, referring 
to the number of phylotypes in an ecosystem. 
Species evenness refers to the relative abun-
dance or proportion of individuals among 
the species. Estimators such as Chao and the 
abundance-based coverage estimator (ACE) 
can be used to estimate the true richness 
(Chao, 1984; Chao & Lee, 1992). Diversity, on 
the other hand, can be indicated with indices 
that combine the dimensions of richness and 
evenness, such as Simpson’s and Shannon’s 
indices for diversity (Shannon, 1948; Simpson, 
1949).
2.3  Irritable bowel syndrome 
(IBS)
2.3.1 Defi ni  on of the disorder
Irritable bowel syndrome (IBS) is a functional 
bowel disorders (Longstreth et al., 2006). Th e 
main symptom is abdominal pain or discom-
fort occurring at suffi  cient frequency in asso-
ciation with defecation-related alterations 
(Longstreth et al., 2006). Th e syndrome aff ects 
10-20% of the Western adults and adolescents 
and has a female predominance (Longstreth 
et al., 2006; Talley, 2008). Th e prevalence in 
Finland is 5.1-16.2%, depending on the crite-
ria used (Hillilä & Färkkilä, 2004). Th e aeti-
ology of IBS is unclear, but several biological, 
physiological and psychosocial factors are 
considered to be involved in the emergence 
of this heterogeneous disorder (Öhman & 
Simrén, 2010). Furthermore, genetics may 
play a role in the syndrome, as shown in a 
twin study (Bengtson et al., 2006). Patients 
have many somatic (gastrointestinal condi-
tions, headache, backache) and psychiatric 
Figure 2. Selected studies of faecal microbiota of healthy subjects based on 16S rRNA gene 
sequencing.
Th e phyla were determined by searching for the sequences using the ribosomal database (RDB) 
classifi er (Cole et al., 2009) or adapted from publications (Andersson et al., 2008; Khachatryan 
et al., 2008; Claesson et al., 2010; Jakobsson et al., 2010). Two subjects were excluded due to a 
diagnosis of UC and the consumption of antibiotics (Claesson et al. 2009); Obese subjects were 
excluded (Turnbaugh et al. 2009); Th ree normal-weighed subjects were included (Zhang et al. 
2009); Y, younger subjects; E, elderly subjects.
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(anxiety, depression, insomnia) comorbidi-
ties (Hillilä et al., 2007). IBS suff erers are not 
predisposed to severe illness, but the intestinal 
disorder signifi cantly diminishes their QOL 
(Si et al., 2004; Tana et al., 2010). Moreover, 
IBS has an economic impact on the society via 
work absenteeism and increased medical costs 
(Hillilä et al., 2010).
2.3.1.1 Diagnos  c criteria
Th e diagnosis of IBS is based on symptoms, as 
no biological markers or distinct physiological 
characteristics are available for the syndrome 
(Clarke et al., 2009). Th e criteria for IBS have 
frequently been refi ned and have so far includ-
ed the Manning (Manning et al., 1978), Rome 
I (Th ompson et al., 1992), Rome II (Th omp-
son et al., 1999) and most recently the Rome 
III (Longstreth et al., 2006) criteria. Most of 
the recently published studies have enrolled 
subjects by applying the Rome II criteria. 
Th e Rome III criteria are as follows: “Recur-
rent abdominal pain or discomfort should be 
observed for at least three days every month, 
for three months consecutively. Th e pain or dis-
comfort has to have two of the following three 
features: Improvement with defecation, onset 
associated with a change in frequency of stool 
or form (appearance) of stool. Furthermore, 
the criterion should be fulfilled for the last 
three months with symptom onset at least six 
months prior to diagnosis” (Longstreth et al., 
2006). Based on the predominant stool habit 
(Lewis & Heaton, 1997), IBS suff erers are fur-
ther classifi ed into the following categories: 
diarrhoea-predominant IBS (IBS-D), consti-
pation-predominant IBS (IBS-C) and mixed 
symptom subtype IBS (IBS-M). In addition, 
patients whose bowel habit symptoms change 
over time are referred to as alternating symp-
tom subtype IBS (IBS-A) patients. Subjects 
who cannot be categorised into these groups 
are referred to as unclassifi ed IBS (Longstreth 
et al., 2006). Th e main modifi cations of the 
criteria in Rome III compared to the previous 
versions relate to the timely demands of symp-
tom duration, i.e. the occurrence of symptoms 
for a period before the diagnosis. Symptoms 
such as mucus in the stool, bloating, straining, 
urgency and the sensation of incomplete evac-
uation are no longer included in the symptom 
criteria, but are listed as supportive symptoms. 
Alarm signs not typical for IBS include onset 
of symptoms at 50 years or older, unintention-
al weigt loss, nocturnal diarrhoea, anemia, 
blood in faeces, and familial history of colon 
cancer, celiac disease or IBD (Khan & Chang, 
2010). In Finland, patients are tested for lac-
tose intolerance and celiac disease before IBS 
diagnosis as the symptoms may resemble IBS 
symptoms (Hillilä, 2009).
2.3.1.2 Treatment
Presently, there is no cure for IBS, but the 
symptoms can be alleviated; Diarrhoea can 
be treated with antidiarrhoeals like loper-
amide, constipation with fi bers and abdomi-
nal pain with antidepressants (Khan & Chang, 
2010). Th e drugs alleviate symptoms for only 
a part of the patients. As the syndrome itself 
does not predispose to severe illness, there is 
a demand for safe treatments without side-
eff ects. Diet changes and avoidance of sress-
full circumstances alleviate the symptoms for 
most of the patients. Furthermore, probiotics 
have shown to alleviate the symptom of IBS as 
discussed later in Section 2.4.
2.3.2 Pathophysiology
Suggested pathophysiological factors in IBS 
include visceral hypersensitivity, immune acti-
vation, abnormal gut motility, secretion and 
permeability, dysfunction in the brain-gut axis 
and altered gut microbiota (Öhman & Simrén, 
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2007; Parkes et al., 2008; Öhman & Simrén, 
2010). Th e distorted interaction between these 
factors contributes to IBS symptoms, which 
are exacerbated by stress (Khan & Chang, 
2010). Low-grade colonic mucosal infl amma-
tion associated with IBS may play a role in the 
pathogenesis, as IBS has similar symptoms to 
UC in remission and celiac disease (Öhman 
& Simrén, 2010). Serine protease activity 
suggested to originate from a perturbed GI 
microbiota in the colon may be a pathophysi-
ological factor in the development of IBS-D 
(Róka et al., 2007). Furthermore, faecal super-
natant from IBS-D caused visceral hypersensi-
tivity and increased paracellular permeability 
in vitro, with a mechanism that was mediated 
by protease-activated receptor two (PAR-
2) (Gecse et al., 2008). Recently, Brint et al. 
(2011) found an altered distribution of toll-
like receptors (TLR) in IBS, indicating a role 
for interactions between the GI microbiota 
and the innate immune system of the host in 
the pathogenesis of IBS.
2.3.2.1 Post-infec  ous IBS
Some patients fulfi l the diagnostic criteria for 
IBS aft er a gastrointestinal infection, when it 
is referred to as post-infectious IBS (PI-IBS). 
Enteric infections caused by bacteria (Cam-
pylobacter, Escherichia coli 0157:H7, Salmo-
nella, Shigella), noroviruses, parasites (Giardia 
duodenalis, Trichinella britovi) or travellers’ 
diarrhoea due to unspecifi ed infectious agents 
have been shown to lead to IBS in 3.7-36% 
of patients (Rodríguez & Ruigómez, 1999; 
Spiller & Garsed, 2009). The predominant 
bowel disturbance in PI-IBS is diarrhoea. Th e 
prognosis for PI-IBS patients is better than for 
IBS patients in general, but the symptoms can 
manifest for years. A severe multi-pathogen 
outbreak caused by E.coli O157:H7 and C. 
jejuni infected over 2300 people in Walkerton 
(Ontario, Canada) and served as a valuable 
cohort for studying PI-IBS, as 36.2% of the 
patients developed IBS aft er 2-3 years of infec-
tion (Marshall et al., 2006). Host genes play-
ing important roles in bacterial recognition, 
infl ammatory responses and epithelial integ-
rity were associated with the development of 
PI-IBS in the same cohort as determined by 
Villani et al. (2010). Antibodies against certain 
bacterial fl agellins have also been more fre-
quently found in patients with IBS, especially 
PI-IBS (Schoepfer et al., 2008).
2.3.2.2  Small intes  nal bacterial 
overgrowth (SIBO)
Antibiotics have been used as therapeutic 
agents in IBS in the context of small intesti-
nal bacterial overgrowth (SIBO) (Parkes et al., 
2008), a condition where bacterial counts in 
the small intestine are elevated. SIBO is sug-
gested to be a marker in IBS (Pimentel et al., 
2000; Pimentel et al., 2003). Th e connection 
between SIBO and IBS is unclear and criti-
cism has been directed at the lactulose/glu-
cose hydrogen breath test (L/GHBT) used 
to diagnose SIBO, which has not been vali-
dated and is unable to properly discriminate 
between healthy and IBS subjects (Posserud 
et al., 2007; Bratten et al., 2008). Furthermore, 
treating IBS patients with antibiotics to reduce 
excessive bacterial counts has been suggest-
ed to suppress the growth of bacteria in the 
colon, rather than in the small intestine (Yu 
et al., 2010). Antibiotics may actually provoke 
functional abdominal symptoms and even 
trigger IBS (Maxwell et al., 2002). Th us, regu-
lar consumption of antibiotics is not recom-
mended.
2.3.2.3  Colonic fermenta  on
Abnormal colonic fermentation, associated 
with alterations in the activity of hydrogen-
Review of the Literature
14
consuming bacteria, has been linked with 
IBS in a study by King et al. (1998), in which 
symptoms in the subjects improved simul-
taneously with a fall in hydrogen and meth-
ane excretion due to an exclusion diet. More 
recently, altered metabolism in protein and 
carbohydrate fermentation has been linked 
to the microbiota in IBS as indicated by Pon-
nusamy et al. (2011) and Tana et al. (2010). 
As common IBS symptoms include bloating 
and fl atulence (Hungin et al., 2003), there is 
thus suggested to be a link between altered 
colonic fermentation and gas in IBS (Parkes 
et al., 2008). Th e gaseous bacterial fermenta-
tion products of undigested carbohydrates in 
the gut microbiota include short-chain fatty 
acids, carbon dioxide, methane and hydro-
gen (Parkes et al., 2008). Moreover, impaired 
handling rather than the load of gas in IBS 
patients has also been suggested trigger symp-
toms (Salvioli et al., 2005).
2.3.2.4 Altera  ons of the microbiota
Th e overall faecal microbiota in IBS has been 
shown with various methods to be diff erent 
from that of healthy individuals (Malinen 
et al., 2005; Kassinen et al., 2007; Codling et 
al., 2009; Noor et al., 2010; Ponnusamy et al., 
2011; Rajilić-Stojanović et al., 2011). Th e IBS-
associated GI microbiota has also been shown 
to be more unstable than that in healthy sub-
jects (Maukonen et al., 2006b). In particular, 
the faecal microbiota of IBS-D patients is the 
most distinct, whereas IBS-C appears to be the 
most similar to that of control subjects devoid 
of gastrointestinal symptoms (Kassinen et al., 
2007; Lyra et al., 2009). Moreover, the diver-
sity and inter-individual variation of IBS relat-
ed faecal microbiota has also diverged from 
that of healthy (Codling et al., 2009; Noor et 
al., 2010; Carroll et al., 2011; Ponnusamy et 
al., 2011). Alterations in the microbiota have 
been seen in all of the main bacterial phyla 
present in the GI tract, i.e. Firmicutes, Bac-
teroidetes, Proteobacteria and Actinobacteria 
(Table 3). Similarly to healthy subjects, nearly 
half of IBS subjects harbour methanogen pro-
ducers (Archaea) (Scanlan et al., 2008a).  Th e 
IBS subtype-specifi c features observed in cul-
ture-independent studies have been recently 
reviewed by Salonen et al. (2010). Th e authors 
stated that the inconsistency of the outcomes 
in the studies of IBS microbiota refl ects a loss 
of homeostasis in the GI tract of IBS patients, 
as a high or low degree of variation is a sign 
of ongoing succession or outgrowth of certain 
taxa in a community, respectively. Further-
more, intestinal ecological dysbiosis was sug-
gested as a pathophysiological factor in IBS, 
meaning that the syndrome is caused by the 
status of community-level multispecies altera-
tions (Salonen et al., 2010a).
Actinobacteria
Alterations in Bifi dobacterium spp. from the 
phylum Actinobacteria have most oft en been 
reported in comparative studies on IBS-relat-
ed microbiota (Table 3). IBS patients have 
been determined to have reduced quantities of 
total bifi dobacteria in their faeces by cultur-
ing (Balsari et al., 1982; Si et al., 2004; Enck et 
al., 2009b) and with molecular methods (Ker-
ckhoff s et al., 2009; Ponnusamy et al., 2011; 
Rajilić-Stojanović et al., 2011). More specifi -
cally, decreased levels of Bifi dobacterium cat-
enulatum have been demonstrated in IBS in 
both faeces (Malinen et al., 2005; Kerckhoff s 
et al., 2009) and mucus (Kerckhoffs et al., 
2009). IBS-D and IBS-C form the extremities 
for the counts of Bifi dobacteria spp. and the 
Collinsella aerofaciens phylotype, as IBS-D had 
reduced and IBS-C elevated levels (Kassinen 
et al., 2007; Lyra et al., 2009).
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Table 3. Comparative studies of the GI microbiota in IBS patients and healthy subjects based on 
culturing and molecular methods applying the 16S rRNA gene.





↓ Bifi dobacterium spp.







Lower biodiversity (F) T-RFLP 21/16 
(Rome III, IBS-D)
faecal+ colonic mucosal 
biopsy
Carroll et al. 2011









(Rome III, children, S)
Saulnier et al. 2011
↑ Staphylococcus aureus qPCR 23/96
(Rome I and II, S)




↓ Bifi dobacterium spp.





Ponnusamy et al. 
20114
↑ number of Lactobacillus spp. (F)





faecal+ colonic mucosal 
biopsy
Carroll et al. 2010
↑ biological variability
↓ biodiversity
↓ Bacteroides vulgatus, B. ovatus, 
   B. uniformis, Parabacteroides spp.
DGGE 22/11
(Rome II, U)
Noor et al. 2010














Tana et al. 20102,4
↑ Ruminococcus torques 94% (IBS-D)
↓ Clostridium thermosuccinogenes 
    85% (IBS-D)
↑ Ruminococcus bromii  (IBS-C) 
↓ Ruminococcus torques 93% (IBS-M) 
qPCR 15/20
(Rome II, S)
Lyra et al. 20103
↓ variation DGGE 33/ 47
(Rome II, U) faecal+ 
9 IBS: colonic mucosal 
biopsy
Codling et al. 2009
↓ Bifi dobacterium spp. Culturing 7765 (ND) Enck et al. 2009
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↓ Bifi dobacterum spp. (F)
↓ Bifi dobacterium catenulatum




Kerckhoff s et al. 
2009
↓ Collinsella aerofaciens
↓ Coprococcus eutactus 97%
↓ Clostridium cocleatum 88%
(↓) Bifi dobacterium catenulatum /
        pseudocatenulatum 
(↑) Ruminococcus torques 94%
16S rRNA gene 
cloning and Sanger 





Kassinen et al. 
20073
↑ instability
↓ Clostridium coccoides -Eubacterium 





Maukonen et al. 
20063
↓ Clostridium coccoides group
↓ Bifi dobacterium catenulatum
↑ Veillonella spp. (IBS-C)
↓ Lactobacillus spp. (IBS-D)
↓ Bifi dobacterium spp. (IBS-D)
qPCR 22/27
(Rome II, S)








Mättö et al. 20053
↑ Eubacterium rectale - Clostridium 
    coccoides -group
FISH 20/20
(Rome II, U)
Ileum and colon muco-
sal biopsy 
Swidsinski et al. 
2005




Si et al. 20042
↓ coliforms
↓ Lactobacillus spp.
↓ Bifi dobacterium spp.
Culturing 20/20
(Manning, U)
Balsari et al. 1982
F, fi nding from faecal samples; M, fi nding from mucosal samples; S, subtyped IBS patients; U, 
unsubtyped IBS patients; HC, healthy controls; qPCR, quantitative real-time polymerase chain 
reaction; DGGE, denaturing gradient gel electrophoresis; FISH, fl uorescent in situ hybridisation; 
TRAC, transcript analysis with the aid of affi  nity capture; TRFLP, terminal restriction fragment 
length polymorphism; 1) Faecal samples if not otherwise mentioned; 2) quality of life (QOL) 
monitored; 3) Samples or fraction of the samples from the same patient cohort; 4) Metabolites 
monitored.
Gram-negative bacteria
Noor et al. (2010) found Bacteroides spp. less 
frequently and in lower quantities in the faeces 
of IBS subjects than in controls. Recently, the 
number of Bacteroides spp. was also decreased 
in IBS in a study by Rajilić-Stojanović et al. 
(2011), but elevated in a study by Ponnusamy 
et al. (2011). Another predominant Gram-
negative phylum in the intestine, Proteobacte-
ria, has shown alterations in association with 
IBS: Enterobacteriaceae have been elevated (Si 
et al., 2004; Mättö et al., 2005) or decreased 
(Balsari et al., 1982) in IBS. Recently, Gam-
maproteobacteria was found to be increased in 
pediatric patients (Saulnier et al., 2011). With 
more specifi c assays of Protebacteria, Pseudo-
monas aeruginosa was recently shown to be 
more frequently detected at elevated levels in 
IBS (Kerckhoff s et al., 2010). 
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Firmicutes
Within the phylum of Firmicutes, Lactobacil-
lus spp. are reported to be increased in unsub-
typed IBS (Tana et al., 2010; Ponnusamy et al., 
2011) and in IBS-D (Carroll et al., 2010). Con-
versely, an early study by Balsari et al. (1982) 
reported reduced quantities of lactobacilli in 
IBS, as did Malinen et al. (2005), in which 
the reduction was seen in IBS-D. Recently, 
17% of IBS patients were found positive for 
Staphylococcus aureus, whereas none of the 
healthy controls were positive (Rinttilä et al., 
2011). Furthermore, increased Veillonella spp. 
has been detected among IBS-C (Malinen et 
al., 2005) and unsubtyped IBS subjects (Tana 
et al., 2010). In the latter study (Tana et al., 
2010), besides higher counts of Veillonella spp. 
and Lactobacillus spp., the levels of acetic acid, 
propionic acid and total organic acids in faeces 
were also higher in the IBS patient samples. In 
addition, patients with high acetic acid or pro-
pionic acid levels had signifi cantly worse GI 
symptoms and QOL. Interestingly, Veillonella 
spp. and Lactobacillus spp. are producers of 
acetic and propionic acid. Treem et al. (1996) 
measured faecal fatty acid concentrations at 
baseline and aft er incubation in vitro with dif-
ferent carbohydrates. Subjects with IBS-D had 
a consistently diff erent pattern of SCFA pro-
duction than controls seen as decreased total 
SCFAs, a lower percentage of acetate, and a 
higher proportion of n-butyrate (Treem et al., 
1996). Furthermore, the abundance of Lacto-
bacillus spp. and Clostridium spp. in IBS was 
recently associated with high levels of amino 
acids and phenolic compounds (Ponnusamy 
et al., 2011).
Studies on the most abundant bacterial 
group in the gut, Clostridium coccoides (also 
known as Clostridium cluster XIV within 
Firmicutes), have reported fewer bacteria of 
this group in IBS patients than in controls 
(Malinen et al., 2005; Ponnusamy et al., 2011). 
Contrary to this, Maukonen et al. (2006) 
observed such reduction only in the IBS-C 
group from the same sample cohort as used 
by Malinen et al. (2005), most probably due 
to the diff erent methodologies used. On the 
mucosa in some IBS patients, the abundance 
of Clostridium XIV group has exceeded 90% 
of the total microbes (Swidsinski et al., 2005). 
Phylotypes of this group have been studied in 
more detail by Kassinen et al. (2007) and Lyra 
et al. (2009). Th e most apparent result is that 
a phylotype with a 16S rRNA gene sequence 
similarity of 94% to a mucus-degrading Clos-
tridium XIV bacterium Ruminococcus torques, 
is abundant in IBS-D (Lyra et al., 2009).
2.4 Probio  cs in IBS
2.4.1 Characteris  cs of probio  cs 
According to the current defi nition by FAO/
WHO, probiotics are: “Live microorgan-
isms which when administered in adequate 
amounts confer a health benefi t on the host” 
(WHO, 2002). Strains of Lactobacillus spp. 
and Bifi dobacteria spp., as well as Propionibac-
terium spp., Enterococcus spp. and Echerichia 
coli and the yeast, Saccharomyces boular-
dii, have most oft en been used as probiotics. 
Probiotics should be safe to the consumer 
and they should also have proven benefi-
cial eff ects on the host. Th e benefi cial eff ects 
seen are strain-specifi c, and thus the results 
obtained cannot be extrapolated to other 
strains. Moreover, each health condition has 
to be evaluated independently (Rijkers et al., 
2010). Probiotics are added to food products 
or consumed as capsules at a typical daily dose 
of approximately 108-1010 cfu. Th e cells should 
remain viable during technological process-
ing, throughout the shelf life of the product 
they are added to, and while passing the GI 
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tract (Rijkers et al., 2010). In addition, prebi-
otics are oft en used with probiotics to gain a 
synergistic eff ect (synbiotics). Prebiotics are 
indigestible food compounds that selectively 
promote the growth or activity of certain bac-
teria (Gibson & Roberfroid, 1995).
2.4.2 Health eff ects in the gut 
Probiotics have long been believed to be ben-
eficial in maintaining enteric homeostasis 
and preventing disease. The first observa-
tions of beneficial lactic acid bacteria were 
made by Metchnikoff  at the beginning of the 
20th century. Probiotics can act in the gut 
lumen by fortifying the colonisation resis-
tance. Th ey may enhance the gut barrier by 
producing antimicrobial agents such as bac-
teriocins and SCFAs that kill pathogens or 
inhibit their growth. Probiotics also compete 
with commensals and pathogens in binding to 
the mucosa and epithelial cells. Furthermore, 
certain probiotics have an eff ect on epithelial 
cells, in which they promote mucus secre-
tion and aff ect gut permeability via epithelial 
cell tight junctions. They may also have an 
immunomodulative eff ects through both the 
innate and adaptive arm of the immune sys-
tem. (Delcenserie et al., 2008; Ohland & Mac-
naughton, 2010).
Specifi c probiotic strains have been dem-
onstrated to be effi  cient in the treatment of 
various GI diseases and conditions, includ-
ing IBS (Table 4). Probiotics have also been 
found to prevent and reduce the duration of 
diarrhoea caused by rotavirus, Clostridium 
diffi  cile, travelling and antibiotics (Wolvers et 
al., 2010). Furthermore, probiotics have been 
shown to help in the eradication of Helico-
bacter pylori and in preventing necrotising 
enterocolitis (NEC) in infants (Wolvers et al., 
2010). Probiotics are eff ective in the maintein-
ance of remission in UC and pouchitis, but 
interestingly are less effi  cient in Crohn’s dis-
ease (CD) (Haller et al., 2010).
2.4.3  Clinical trials of probio  cs in 
IBS
Studying the eff ects of probiotics in IBS is jus-
tifi ed by several reasons. Th e current medi-
cal treatments for IBS patients are low in 
effi  ciency and many predispose to many side 
effects (Khan & Chang, 2010), and there is 
thus a need for better and safer treatments, 
the criteria which probiotics might meet. Th e 
GI microbiota in IBS has also proven to be 
aberrant in comparison to healthy subjets, as 
reviewed in section 2.3.2.4. Furthermore, pro-
biotics are suggested to be able to modulate 
gut transit, visceral hypersensitivity, intestinal 
gas production and infl ammatory responses 
(Haller et al., 2010), which are all important 
factors in IBS (see section 2.3.2).
Th e symptoms of IBS have been moni-
tored in many large randomised placebo-con-
trolled trials with diff erent probiotic strains, 
including studies using multispecies probi-
otic mixtures (Table 4). L. rhamnosus GG 
has been the most frequently used probiotic 
strain as it has been used in six out of 27 tri-
als. Th e potential mechanism of action associ-
ated with alleviation of symptoms of IBS has 
been reported in some of the studies. Delay in 
colonic transit was shown in IBS-D patients 
receiving VSL#3 (Bifi dobacterium longum, B. 
infantis, B. breve, Lactobacillus acidophilus, L. 
casei, L. deldrueckii subsp. bulgaricus, L. plan-
tarum, Streptococcus salivarius subsp. ther-
mophilus) (Kim et al., 2005). In another study 
with a probiotic mixture with L. rhamnosus 
GG, L. rhamnosus Lc705, Propionibacterium 
freudenreichii ssp. shermanii JS and B. anima-
lis ssp. lactis Bb12 the supplement appeared 
to stabilise the microbiota composition 
(Kajander et al., 2008). In a study with a single 
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strain of B. infantis 35624 the interleukin (IL)-
10/IL-12 ratio, which has been shown to be 
low in IBS, was normalised (O’Mahony et al., 
2005). More recently, L. rhamnosus GG nor-
malised the increased intestinal permeability 
of children with IBS (Francavilla et al., 2010).
Th e eff ects of probiotic interventions on 
IBS are diffi  cult to compare due to diff erences 
in probiotic strains and doses used, the dura-
tion of the studies, small number of subjects 
and overall study designs (McFarland & Dub-
lin, 2008; Spiller, 2008; Brenner et al., 2009; 
Hoveyda et al., 2009; Moayyedi et al., 2010; 
Parkes et al., 2010) (Table 4). A high placebo 
response has also been characteristic in these 
studies. With caution it may be concluded, 
that both single and multiple strain probiotic 
supplements of various strain types have more 
oft en been eff ective than uneff ective (in 22 out 
of 27 studies). Th e eff ect of the probiotic the-
raphy has been more pronounced on the GI 
symptoms than on the quality of life (positive 
eff ect of QOL in six out of 12 studies) (Table 
4).
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3. AIMS OF THE STUDY
Th e aims of this study were to:
I Determine the bacterial phylotype content of the GI microbiota of healthy controls and IBS-
D subjects applying 16S rRNA gene cloning and sequencing of %G+C fractionated faecal 
DNA samples pooled from several individuals (studies I and II).
II Compare the GI microbial community of IBS-D subjects with that of healthy subjects using 
16S rRNA gene sequencing data (study II).
III Characterise the relationship between IBS associated GI microbiota phylotypes and self-
reported IBS symptoms (study III).
IV Monitor the GI phylotypes and IBS symptoms during a multispecies probiotic intervention 
(study IV).
Aims of the Study
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4. MATERIALS AND METHODS
4.1 Study subjects
Th e recruitment of healthy subjects was coor-
dinated by the Technical Research Centre of 
Finland (VTT) (I and II). The IBS subjects 
were recruited by Valio Ltd (II, IV) and Kuo-
pio Harjula hospital (III) (Table 5). Th e IBS 
subjects fulfi lled the Rome I (III) or Rome II 
(II, IV) criteria. Subjects or a subset of these 
subjects have previously been used in the fol-
lowing studies: Kajander et al. (2005), Kajan-
der et al. (2007), Kassinen et al. (2007), Lyra et 
al. (2009), Malinen et al. (2005), Maukonen et 
al. (2006b), Mättö et al. (2005) and Rinttilä et 
al. (2011).
Th e study protocols for the healthy sub-
jects participating in studies I and II were 
approved by the Ethical Committee of the 
Technical Research Centre of Finland (VTT). 
Th e study protocols for IBS subjects in studies 
II and IV were approved by the Human Eth-
ics Committee of the Joint Authority for the 
District Hospital of Helsinki and the Uusimaa 
region. Th e study protocol for study III was 
approved by the Research Ethics Committee 
of Kuopio University Hospital. All partici-
pants provided written informed consent and 
were allowed to withdraw from the study at 
any point.
4.2 Study methods
An overview of the methods applied in this 
study is given in Figure 3. Th e methods used 
are listed in Table 6. Th e phylogenetic analy-
ses and library comparisons are visualised in 
Figure 4, while the qPCR assays are listed in 
Table 7.
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1) Bowel habit: D, diarrhoea; C, constipation; M, mixed; ND, not determined (in study II the average age of 
the subjects could not be determined as the corresponding age for a missing sample could not be removed 
from the data). 2) Seq, subject samples used in percentage of guanine plus cytosine fractioning and sequenc-
ing; qPCR, subject samples used in quantitative real-time PCR analysis. 3) Probiotic supplementation with 
Lactobacillus rhamnosus GG (ATCC 53103), L. rhamnosus Lc705 (DSM 7061), Propionibacterium freuden-
reichii ssp. shermanii JS (DSM 7067) and Bifi dobacterium breve Bb99 (DSM 13692).
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Figure 3. A fl ow chart of the study protocols in this thesis.











Table 6. Methods used in studies I-IV.
Laboratory methods Study (Table)
DNA isolation from faecal samples I, II, III, IV
DNA quantifi cation I, II, III, IV
%G+C profi ling and fractioning in 5% intervals I, II
Purifi cation of %G+C fractions I, II
16S rRNA gene clone library construction I, II 
Sequencing of clone libraries I, II 
qPCR II, III, IV, Table 7
Other methods Study (Figure)
Sequence analysis and community comparisons I, II, Figure 4
Mann-Whitney U-test II, III, IV
Th e Pearson’s χ2 test III
PCA III, IV
Linear models (ANOVA, F-test, t-test) III, IV
Clinical studies and laboratory tests of patients III
Questionnaire regarding GI symptoms IV
Questionnaire regarding QOL and GI symptoms III
%G+C, percentage of guanine plus cytosine; qPCR, quantitative real-time polymerase chain reac-







Figure 4. Th e community comparisons performed for clone library 16S rRNA gene sequences.
I, Study I; II, Study II; HC, healthy controls; IBS-D, diarrhoea-predominant irritable bowel syn-
drome; %G+C, percent guanine plus cytosine; OTU, operative taxonomic unit.
Table 7. Group and phylotype specifi c real-time PCR assays applied in this study and the rationale 
to their use. 
Assay (Phylum)1 Assay’s reference Association to IBS vs. HC 
(reference)
Study
Eggerthella lenta–like (A) II ↑ IBS-D (In sequence library 
   comparison, II)
II
Enterobacteriaceae (P) II ↑ IBS-D (In sequence library
   comparison, II)
II
Bifi dobacterium spp. (A) Rinttilä et al. 2004 ↓ IBS-D (NS, Malinen et al. 




Kassinen et al. 2007 ↓ (NS, Kassinen et al. 2007) III
Clostridium coccoides/ Eubacte-
rium rectale-group (F)
Rinttilä et al. 2004 ↓ (NS, Malinen et al. 2005) III
Desulfovibrio desulfuricans-group 
(P)
Rinttilä et al. 2004 ↓ IBS-D (NS, Malinen et al. 
   2005)
III
Eubacterial 16S (All eukaryotic 
phyla)
Kassinen et al. 2007  - III
Lactobacillus -group (F) Rinttilä et al. 2004 ↓ IBS-D (vs. IBS-C, Malinen 




Kassinen et al. 2007 ↑ (NS, Kassinen et al. 2007) III
Veillonella spp. (F) Rinttilä et al. 2004 ↑ IBS-C (Malinen et al. 2005) III
Clostridium cocleatum 88% (F) Kassinen et al. 2007 ↓ (NS, Kassinen et al. 2007; 
   IBS-D1, Lyra et al. 2009)
III, IV
Collinsella aerofaciens-like (A) Kassinen et al. 2007 ↓ (Kassinen et al. 2007, IBS-
   D+IBS-M, Lyra et al. 2009)
III, IV
Coprococcus eutactus-like (F) Kassinen et al. 2007 ↓ (Kassinen et al. 2007) III, IV
Ruminococcus torques 91% (F) Kassinen et al. 2007 ↑ IBS-D+IBS-M (Lyra et al. 
   2009)
III, IV
Ruminococcus torques 94% (F) Kassinen et al. 2007 ↑ (NS, Kassinen et al. 2007; 
   IBS-D, Lyra et al. 2009)
III, IV
Bacteroides intestinalis-like (B) Lyra et al. 2009 ↓ IBS-D2 (Lyra et al. 2009) IV
Clostridium thermosuccinogenes 
85% (F)
Lyra et al. 2009 ↓ IBS-D1 (Lyra et al. 2009) IV
Ruminococcus torques 93% (F) Lyra et al. 2009 ↑ IBS-M (Lyra et al. 2009) IV
1) Th e percentage indicates the 16S rRNA gene similarity to the nearest cultured bacterial species, 
‘–like’ indicates over 98% similarity. A, Actinobacteria; B, Bacteroidetes; F, Firmicutes; P, Proteo-
bacteria; ↑, increase; ↓, decrease; NS, result statistically non-signifi cant; 1, Outcome in IBS-M in 
addition to HC; 2, Outcome in IBS-C in addition to HC.
Materials and Methods
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5. RESULTS AND DISCUSSION
5.1  Community analysis of a 
healthy GI microbiota (I)
Th e microbiota of the human GI tract is char-
acterised by an abundance of uncultured bac-
teria most oft en assigned to the phyla Firmi-
cutes and Bacteroidetes (Figure 2). However, 
it has been suggested that high G+C bacte-
ria (Actinobacteria) are underrepresented in 
many culture-independent studies (Harmsen 
et al., 2000; Khachatryan et al., 2008). To com-
prehensively evaluate the human intestinal 
microbiota across the full range of its genomic 
G+C content (25-75%), a %G+C profi led and 
fractionated faecal bacterial DNA sample 
pooled from 23 individuals was cloned, and 
the 16S rRNA genes were partially Sanger 
sequenced (Table 5, Figure 3, Table 6). Th ree 
fractions (%G+C 25-30, 40-45, 55-60) were 
initially cloned and sequenced by Kassinen et 
al. (2007), and this study completed the work 
on seven fractions. In the %G+C fractiona-
tion approach, the genomic DNA exposed to 
bisbenzimidazole is centrifuged in a caesium 
chloride (CsCl) gradient and thereaft er frac-
tionated. Th e denser DNA with a high G+C 
content migrates to the bottom of the CsCl 
gradient during high speed centrifugation, as 
the bisbenzimidazole preferably bind to ade-
nine and thymine and aff ects the buoyant den-
sity of DNA (Holben & Harris, 1995). Parti-
tioning of the complex microbiota into %G+C 
fractions with 5% increments aided in a closer 
observation of the genomic high %G+C bac-
teria. Furthermore, the method restrained the 
overamplification of dominant species that 
would have obscured the less prevalent ones. 
Th e 16S rRNA gene clones from the complete 
microbiota %G+C profi le, were further ana-
lysed phylogenetically and statistically (Table 
6, Figure 4). For comparison, an unfraction-
ated but otherwise analogously cloned and 
sequenced sample was prepared from the 
same pool of microbiota DNA.
5.1.1  Phylum distribu  on
Th e acquired 3199 sequences from the com-
bined fractionated sample libraries of healthy 
volunteers represented 455 OTUs, and the 
459 sequences from the unfractionated sam-
ple represented 131 OTUs with the applied 
98% sequence similarity criterion. Th e %G+C 
fractioning prior to cloning and sequencing 
enhanced the recovery of sequences affi  liat-
ing with Actinobacteria (26.6%) by over sev-
en-fold compared with the unfractionated 
sample (3.5%). Meanwhile, the proportion of 
Firmicutes decreased from 93.2% to 68.5% as 
an increase in the proportion of one phylum 
reduces that of the others (Table 2 in study I). 
Th e proportion of sequences affi  liating with 
Actinobacteria in the unfractionated sam-
ple analysed in this study is comparable with 
previous estimations applying conventional 
16S rRNA cloning and sequencing without 
%G+C fractionating, which yielded 0-6% of 
the detected intestinal microbiota (Figure 2). 
Th e relative proportions of less abundant Bac-
teroidetes and Proteobacteria in the microbiota 
were less aff ected by the %G+C fractionation 
of the faecal DNA sample prior to sequencing 
(3.1% to 2.8% and 1.3% to 0.2%, respectively) 
(Table 2 in study I). The phylum distribu-
tion of the combined fractions did not diff er 
much aft er proportioning them according to 
the DNA content in each fraction (Figure 5). 
However, the %G+C profi le fractions repre-
sent individual cloning and sequencing exper-
iments, in which an equal number of clones 
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was sequenced, despite the diff erent propor-
tional amounts of DNA within the fractions, 
and quantitative conclusions should therefore 
be drawn with caution. 
5.1.2  Observa  ons on the %G+C 
frac  ons 
Th e distribution of phyla between the indi-
vidual clone libraries of the fractionated sam-
ple revealed that Firmicutes mostly settled 
in the lower %G+C content portion of the 
profile, whereas Actinobacteria were found 
in the fractions with a %G+C content rang-
ing from 50% to 70% (Figure 5). Sequences 
in these fractions also had the highest %G+C 
contents in their 16S rRNA gene sequences, 
ranging from 58% to 62% (Table 1 in study 
I). In fact, %G+C fractions 30-50 yielded a 
similar phylotype distribution to the unfrac-
tionated library, were dominated by the Firmi-
cutes (Clostridium clusters XIV and IV), and 
accounted for 54% of the profi led DNA. How-
ever, %G+C fractions 50-70 were dominated 
by Actinobacteria, comprising 41% of the 
total DNA in the original fractionated sample 
(Figure 5). %G+C fractions 50-60 had a com-
paratively lower diversity and a higher abun-
dance with bifi dobacteria than %G+C fraction 
Figure 5. Th e %G+C profi le of pooled faecal microbial DNA from healthy subjects and the distri-
bution of bacterial phyla in separate %G+C fractions and in the unfractionated DNA sample pool.
Th e phyla were determined according to the the Ribosomal Database Project Classifi er (Wang et 
al., 2007) with a bootstrap confi dence level of 80%. Th e Clostridium clusters were determined by 
a combined Clustal W alignment (Th ompson et al., 1994) with reference sequences classifi ed into 
16S rRNA gene clusters according to Collins et al. (1994). Th e distribution of the Clostridium clus-
ters IV and XIV within the Firmicutes was represented by 23.5% and 33.0%, respectively, of the 
total sequences in the unproportioned count. Whereas, the actinobacterial phylotypes consisted 
of the orders Bifi dobacteriales, Coriobacteriales and Actinomycetales, accounting for 12.4%, 13.4% 
and 0.8% of the sequences, respectively. U, Phyla unpropotioned with DNA amount in %G+C 
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45-50, with sequences affi  liating mainly with 
Clostridium clusters IV and XIV and having a 
higher diversity according to Shannon entro-
pies (Additional fi le 2 in study I). Th is could 
be due to the higher heterogenity among 
clostridia and more uniform bifi dobacterial 
16S rRNA gene sequences compared to clos-
tridia. According to SONS analysis (Schloss & 
Handelsman, 2005), at least 80% of sequences 
from low %G+C fractions (30-40%) were 
shared with the unfractionated sample. How-
ever, in the high %G+C content fractions (55-
65%), the proportion of shared sequences was 
only 33%. Th is further supports the conten-
tion that the sequences from unfractionated 
community samples mostly represent phylo-
types from low G+C bacteria.
5.1.3  Methodological fi ndings
In this study, the Actinobacteria outnumbered 
Bacteroidetes as in the pyrosequencing study 
by Andersson et al. (2008) and the metagen-
omic study by Gill et al. (2006), in which no 
Bacteroidetes at all were found. A technical 
point conserning the outcome is that the rig-
orous DNA extraction method used in this 
study may have raised the DNA yield from 
robust Gram-positive bacteria and thus low-
ered the proportion of DNA from more easily 
lysed Gram-negative bacteria (Bacteroides) in 
both fractionated and unfractionated samples. 
However, also a delay or inadequate tempera-
ture in freezing may lower the proportion of 
Bacteroidetes detected, as discussed in Salonen 
et al. (2010).
Th e unfavourable PCR reaction condi-
tions involved in the amplifi cation of a highly 
diverse community sample like the GI micro-
biota is one cause for the discrimination of 
Actionobacteria in many studies as discussed 
in section 2.2. As an example, a comparative 
study of a metagenomic library and a library 
constructed from 16S rRNA gene clones 
showed that Actinobacteria were more abun-
dant in the former (16% vs. 6%), in which 
PCR bias did not aff ect the outcome (Man-
ichanh et al., 2008). Moreover, an unexpected-
ly low frequency and abundance of bifi dobac-
teria in infant faecal microbiotas possibly due 
to methodological limitations was observed in 
a study by Palmer et al. (2007). It is generally 
known that DNA with a high G+C content 
is amplifi ed less effi  ciently compared to the 
DNA with a lower G+C content. Primers and 
other factors in a PCR reaction may also cause 
a bias as, for example, ‘universal’ primers may 
discriminate Actinobacteria (Farris & Olson, 
2007). Th is was overcome in Hill et al. (2010) 
using the cpn60 gene as a phylogenetic mark-
er. It is thus good to question the predominant 
use of the 16S rRNA gene in the phylogenetics 
of microbial communities.
Th e sequencing step in the community 
analysis may also introduce errors in the com-
munity structure. In this study, the sequenc-
ing conditions had to be modifi ed for several 
clones in the high %G+C fractions (60-70% 
G+C content). These clones were mem-
bers of the order Coriobacteriales and had 
an extremely G+C-rich region in which the 
sequencing reaction had stopped. In a high 
throughput community analysis, these kind 
of clones can easily be hidden, as the ‘opti-
mal’ conditions are less optimal for the high 
G+C bacteria, which have thus been rare or 
absent in earlier 16S rRNA gene-based clone 
libraries of the intestinal microbiota. Indeed, 
over half of the actinobacterial OTUs in our 
study belonged to the order Coriobacteriales 
after dimethyl sulphoxide treatment of the 
sequencing reaction mixtures, which was used 
to prevent self-complementarity and loop for-
mation in G+C-rich DNA regions.
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5.1.4  Abundance of 
Coriobacteriales
Bifi dobacteria (order Bifi dobacteriales) have 
received considerable attention in research on 
the GI microbiota, due to their proven ben-
efi cial eff ects in hosts. Th erefore, it is some-
what surprising that a large proportion of GI 
community analysis reports have used meth-
ods that overlook them (Figure 2). Propioni-
bacteria (order Actinomycetales) also display 
probiotic properties (Cousin et al., 2010). 
In this respect, the probiotic potential of the 
third actinobacterial order within the GI tract 
(Coriobacteriales), which is phylogenetically 
close to the previous ones and highly abun-
dant according to this study (Figures 2 and 3 
in study I), warrants attention.
Previous studies have demonstrated 
that low abundances of members of the fam-
ily Coriobacteriaceae within the Actinobacte-
ria have been associated with a high risk of 
colon cancer (Collinsella aerofaciens) (Moore 
& Moore, 1995), CD (Atopobium group) 
(Manichanh et al., 2006), IBS (C. aerofaciens–
like phylotype) (Kassinen et al., 2007) and a 
familial disease causing Mediterranean fever 
(Atopobium group) (Khachatryan et al., 2008). 
Th erefore, in addition to the more intensively 
studied bifi dobacteria and propionibacteria, 
other actinobacterial genera such as Corio-
bacteriaceae may also be associated with the 
health status. However, more detailed data 
are required to assess their role in health and 
disease. Moreover, Jakobsson et al. (2010) 
recorded a dramatic decline in Actinobacteria 
aft er clarithromycin and metronidazole treat-
ment while Mäkivuokko et al. (2009) reported 
reduced quantities of C. aerofaciens in elderly 
subjects using non-steroidal anti infl amma-
tory drugs (NSAIDs). In addition, newborns 
from mothers treated with antibiotics during 
pregnancy or born by Caesarean section had 
lower proportions of members of Atopobium 
cluster in their gut microbiota (Fallani et al., 
2010).
Finns and Swedes both have high lev-
els of Actinobacteria (Mueller et al., 2006; 
Andersson et al., 2008; Jakobsson et al., 2010) 
(study I). Similarities in dietary habits, could 
explain such trends. C. aerofaciens has been 
shown to decrease in subjects on a reduced 
carbohydrate weight loss diet (Walker et al., 
2011b), while the consumption of galacto-
oligosaccharides (GOS) or fructo-oligosac-
charides (FOS) has been reported to increase 
Bifidobacterium adolescentis and C. aerofa-
ciens activity in the gut (Tannock et al., 2004). 
Moreover, children in a rural African village 
with a high fibre diet have been shown to 
have increased overall levels of Actinobacte-
ria compared to Europeans (De Filippo et al., 
2010). In addition to increased activity, a diet 
rich in GOS and FOS could in the long term 
increase the counts of Actinobacteria. A study 
on European infants has shown that a north-
south gradient exist with a higher proportions 
of Bifi dobacteria spp. and Atopobium cluster 
in the north (the most northern and southern 
study populations were Swedes and Spanish, 
respectively) (Fallani et al., 2010). It is note-
worthy that in Scandinavian countries breast-
feeding rates are high and infants are weaned 
late (Yngve & Sjöström, 2001), which elevates 
the count of Bifidobacteria spp. and Atopo-
bium cluster bacteria (Fallani et al., 2010). 
Notably, two studies on Swedish subjects were 
conducted by the same research group and the 
microbial DNA isolation method described 
was the same (Andersson et al., 2008; Jakobs-
son et al., 2010), thus strongly infl uencing the 
phylum-level outcome of the studies (Salo-
nen et al., 2010b). The used methodology 
may also be a significant issue in the other 
large-scale sequencing studies on microbiota 
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performed in same laboratories and report-
ing low amounts of Actinobacteria in the GI 
microbiota of healthy individuals (Figure 2).
5.2  Comparison of the GI 
microbiota of IBS-D and 
healthy individuals (II)
Th e GI microbiota in IBS-D diff ers from other 
IBS symptom subtypes and has many special 
features, as reviewed in section 2.3. In this 
study, the GI microbiota of IBS-D subjects was 
analysed and the microbial community was 
compared with that of healthy controls (HC). 
The libraries were constructed analogously 
by using %G+C profiling and fractionation 
combined with 16S rRNA gene clone library 
sequencing, as described in study I (Table 
5, Figure 3, Table 6, Figure 4). As in study I, 
three fractions (%G+C 25-30, 40-45, 55-60) 
were initially cloned and sequenced by Kas-
sinen et al. (2007), and this study completed 
the sequencing work. Furthermore, a closer 
quantification of an interesting phylotype 
(Eggerthella lenta–like) and group (Enterobac-
teriaceae) was performed with qPCR on the 
individual samples (Table 7).
5.2.1 Characteris  cs of the libraries
Th e pooled sample from IBS-D patients (n = 
10) resulted in a total of 3267 sequences and 
302 OTUs with the applied 98% cut-off  level 
for OTUs. Th e set was compared to the pooled 
sample of healthy controls (n = 23) that com-
prised 3199 sequences and substantially more 
OTUs, in total 428 (Table 1 in study II). Th e 
sequence pool from both community samples 
altogether made up 578 OTUs, of which 30.4% 
were shared. Th e portion of sequences shared 
between the two samples was 81.0% (study 
II, Figure 4). According to Good’s formula 
(Good, 1953), the coverage of clone libraries 
was above 95%, which is much lower than 
in pyrosequencing studies (Andersson et al., 
2008), but the same magnitude was observed 
in both groups, which is important in a com-
parative study (Table 1 in study II). Th e IBS-
D library contained fewer unique sequences 
and OTUs than the HC library (Figure 4 in 
study II). In addition to a lower quantity of 
OTUs, lower Shannon and Simpson indices 
for diversity as well as Chao and ACE richness 
estimates were observed in the IBS-D library 
compared to the HC library (Table 1 in study 
II). Th e lower number of individuals in the 
IBS-D sample most likely caused at least part 
of the lower diversity and uniqueness in IBS-
D sequence library as well as bowel habit in 
IBS-D, as diarrhoea itself has been shown to 
disrupt the microbial ecology and reduce the 
overall microbial count in the bowel (Mai et 
al., 2006). Diversity in any ecosystem is gen-
erally thought to be important, as it creates 
stability and prevents dominance by a single 
species. It also helps in coping during stress-
ful events in the ecosystem, as several species 
can handle same tasks. A reduced bacterial 
diversity has very recently been detected also 
in another IBS-D cohort (Carroll et al., 2011) 
as well as in a stydy with unsubtyped IBS 
patients (Noor et al., 2010), in infl ammatory 
intestinal diseases like such as CD (Seksik et 
al., 2003; Dicksved et al., 2008), and in infants 
with NEC (Wang et al., 2009). Th e rank abun-
dance curves of the libraries showed highly 
similar OTU evenness and therefore a similar 
community structure in terms of the number 
of OTUs and the sequence count within 
OTUs, but did not indicate the type of species 
they represented (Figure 2 in study II).
5.2.2 Phylum level diff erences
Th e phylum-level microbial community com-
parison with the Ribosomal Database Project 
(RDP) classifi er (Cole et al., 2009) revealed 
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that the IBS-D library had signifi cantly more 
sequence representatives of Proteobacteria 
and Firmicutes than the HC library, and fewer 
representatives of Actinobacteria and Bacter-
oidetes (Figure 3 in study II). Th e fi nding con-
cerning the three latter phyla is in accordance 
with a cohort of all IBS symptom subtypes by 
Rajilić-Stojanović et al. (2011). Furthermore, 
the comparison made with OTUs revealed 
that the IBS-D library was signifi cantly richer 
in Firmicutes than the HC library. Diff erences 
at such a high taxonomic level are less prone 
to be biased by differences in the subject 
number. Th e number of sequences of the phy-
lum Bacteroidetes was lower in the IBS-D than 
the HC library, but low overall in both librar-
ies. Th is was possibly due to technical issues, 
as discussed in study I.
5.2.3 Core phylotypes
Tap et al. (2010) determined the core OTUs 
among 17 subjects (vegetarians and omni-
vores from the Netherlands and France) with 
a criterion of 50% of the subjects harbouring 
the OTU. Th e 578 common OTUs for IBS-D 
and HC in this study were compared with full-
length public database representatives of the 
66 core OTUs (Firmicutes 57, Bacteroidetes 
7, Actinobacteria 2) determined by Tap et al. 
(2010). As a result, 57 of the 66 core OTUs 
were detected among the common OTUs in 
this study. Of the core OTUs detected in this 
study, one and ten OTUs had sequence rep-
resentatives in only the IBS-D or HC library, 
respectively, suggesting that the IBS-D library 
is less diverse and resilient to core species.
5.2.4 Lachnospiraceae
A marked proportion of the sequences and 
OTUs in IBS-D (45% and 41%) and HC (33% 
and 30%) libraries affi  liated with the family 
Lachnospiraceae, which diverged signifi cantly 
between the community samples in the RDP 
Library Compare analysis (Additional file 
3 and 4 in study III). Related to this fi nding, 
serum antibodies to certain fl agellins that are 
expressed by Clostridium XIV bacteria are ele-
vated in CD (Lodes et al., 2004). One of these 
antibodies had a high amino acid similarity 
with a fl agellin gene belonging to Clostridium 
cluster XIV bacteria (Duck et al., 2007). Anti-
bodies against these bacterial fl agellins were 
found more frequently in patients with IBS, 
especially PI-IBS patients, making an inter-
esting link between IBS and CD (Schoepfer et 
al., 2008). Th e abundance of Lachnospiraceae 
in IBS-D in this study supports this fi nding, 
although the result does not provide any more 
specifi c qualitative information on the appear-
ance of this group within the IBS-D and HC 
GI communities. As pointed out by Salonen 
et al. (2010), Lachnospiraceae was increased in 
patients with Clostridium diffi  cile associated 
diarrhoea (CDAD), but not in IBD although 
these three diarrhea-causing GI conditions 
shared many similarities in the GI microbiota 
(Frank et al., 2007; Khoruts et al., 2010). Pre-
viously, the Clostridium coccoides - Eubacte-
rium rectale group (Clostridium cluster XIV) 
has been detected in IBS patients with con-
tradictory results (Malinen et al., 2005; Mättö 
et al., 2005) (Table 3). Th e reason for this dis-
crepancy is most probably that the group is 
too broad to be analysed with one assay.
5.2.5 Quan  ta  ve real-  me PCR
Altogether 130 and 8 Gammaproteobacte-
ria sequences were seen in IBS-D and HC 
clone libraries, respectively (Additional file 
4 in study II). Moreover, a single phylotype 
seemed to dominate in IBS-D sample (Figure 
1 in study II). Therefore, a qPCR assay was 
developed and used to identify this Entero-
bacteriaceae –like phylotype (Table 7). An 
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increase was seen in the Enterobacteriaceae 
phylotype in IBS-D, although it was nonsig-
nifi cant (p = 0.28) (Figure 6A in study II). Th e 
%G+C fractionation enabled the observa-
tion of differences in Gammaproteobacteria 
between HC and IBS-D. Only one sequence of 
this class was obtained in the unfractionated 
library of HC in study I, whereas the fraction-
ated sample also contained sequences of other 
classes of Proteobacteria (Table 2 in study I). 
Proteobacteria are clinically relevant bacteria, 
since they include many pathogens or oppor-
tunistic pathogens. However, the pathogenic-
ity of gammaproteobacterial strains cannot 
be determined from the 16S rRNA gene. Ker-
ckhoff s et al. (2010) suggested Pseudomonas 
aeruginosa to have a role in the pathophysiol-
ogy of IBS, as this Gammaproteobacteria was 
found more frequently and at higher abun-
dances in small intestinal brush samples and 
faeces of all IBS patient groups than in healthy 
subjects. Interestingly, increase of Gammapro-
teobacteria was recently also detected in chil-
dren with IBS (Saulnier et al., 2011) and the 
abundance was found to be associated with 
IBS-symptoms in adults (Rajilić-Stojanović et 
al., 2011).
In accordance with this study, also CD 
is associated with the abundance of entero-
bacteria and gammaproteobacteria (Seksik 
et al., 2003; Walker et al., 2011a), including 
opportunistic pathogens (Martinez-Medina 
et al., 2006), such as Pseudomonas areuginosa 
in IBS (Kerckhoff s et al., 2010). Interestingly, 
increased expression levels of TLR-4 that 
recognise lipopolysaccharides of Gram-neg-
ative bacteria were observed in IBS patients’ 
biopsy samples, although in lower amounts 
than in those of IBD patients’ (Brint et al., 
2011). Furthermore, Gammaproteobacteria 
are abundant in post-gastric bypass individu-
als (Zhang et al., 2009) and in preterm infants 
with NEC (Wang et al., 2009). In addition, a 
lower abundance of Enterobacteriaceae within 
the Gammaproteobacteria and lower levels of 
SCFAs have been observed in EU children 
compared to children in a rural African village 
on a fi bre-rich diet (De Filippo et al., 2010). 
Th us, the abundance of Gammaproteobacteria 
can be an indicator of an unfavourable or dis-
torted microbiota in many conditions. Lupp 
et al. (2007) demonstrated that infl ammation 
supported the growth of aerobic bacteria in 
mice, especially Enterobacteriaceae, and that 
the simultaneous precence of an enteropatho-
gen and inflammation reduced the number 
of colonic bacteria. Th e low diversity of the 
whole faecal microbiota and high abundance 
of enterobacteria in IBS-D in this study may 
thus refl ect infl ammation in IBS.
Furthermore, an Eggerthella lenta–like 
phylotype was quantifi ed with qPCR (Table 
7), since the genus seemed to be signifi cantly 
elevated in IBS-D samples (Additional fi le 4 in 
study II) according to the RDP Library Com-
pare analysis (Cole et al., 2009). The result 
revealed an opposite though nonsignificant 
(P = 0.42) trend (Figure 6B in study II), and 
was thus in accordance with the association of 
the healthy microbiota with Coriobacteriaceae 
(see study I). Th is observation demonstrated 
the importance of analysing individual sam-
ples to obtain quantitative data.
5.3  GI symptom and microbiota 
in IBS (III)
Abdominal pain or discomfort is the hallmark 
symptoms of IBS. Th e symptoms may improve 
with defecation or their onset can be associ-
ated with alterations in stool form and fre-
quency (Longstreth et al., 2006). Other com-
monly reported symptoms include urgency 
and straining during defecation, bloating, 
mucus in the stool and the feeling of incom-
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plete evacuation (Khan & Chang, 2010). 
As the GI microbiota has been shown to be 
altered in IBS (see section 2.3.2.4), it is reason-
able to hypothesise that there is a link between 
the GI microbiota and GI symptoms that lead 
to impaired QOL (Khan & Chang, 2010). 
Therefore, the association of certain bacte-
rial groups or phylotypes previously linked 
to either the microbiota of IBS subjects or 
healthy controls and self-reported symptoms 
experienced by IBS subjects were examined in 
study III (Table 5, Table 7). Th e composition 
of the GI microbiota was investigated with 
thirteen qPCR assays, after which associa-
tions between quantities or prevalences of the 
selected bacterial groups or phylotypes and 
various IBS-related symptoms experienced by 
the patients were investigated.
5.3.1 Microbiota and GI symptoms
Visualisation of the principal component 
analysis (PCA) results revealed a positive 
association between the Ruminococcus torques 
94% phylotype (94% 16S rRNA gene sequence 
similarity to R. torques) and the bowel symp-
toms, both separately and jointly (Figure 1A 
and B in study III). Abdominal pain, which 
is the keystone symptom in IBS, associated 
most strongly with R. torques 94% among the 
individual bowel symptoms in the PCA (study 
III, Figure 1b). Furthermore, the presence and 
abundance of R. torques 94% was linked to the 
severity of bowel symptoms (study III, Table 
7). Previously, R. torques 94% has been associ-
ated with IBS-D (Lyra et al., 2009). R. torques 
belongs to the Clostridium coccoides group 
(XIV), which is generally thought to be the 
most prevalent group in the gut. Unlike many 
other members of C. coccoides group XIV, R. 
torques is not a benefi cial butyrate producer 
(Dethlefsen et al., 2006). Instead, R. torques 
efficiently degrades mucin and has been 
associated with CD (Martinez-Medina et al., 
2006; Png et al., 2010; Joossens et al., 2011), 
as has the phylotype R. torques 94% (Frank et 
al., 2007). Th e passage of mucus is a reported 
symptom in IBS that could be linked to the 
abundance of R. torques 94%, but was not 
inquired from the participants in this study. 
Bacterial fl agellins possibly play a role in IBS 
aetiology as they provoke antibody (Schoepfer 
et al., 2008) and TLR-5 (fl agellin recognition) 
expression in IBS patients (Brint et al., 2011). 
Moreover, the presence of R. torques 94% had 
a negative eff ect on the abundance of Copro-
coccus eutactus 97%, Collinsella aerofaciens–
like, and Clostridium cocleatum 88% phylo-
types according to linear models (study III, 
Table 7) with all three latter phylotypes being 
associated with healthy microbiota (Kassinen 
et al., 2007; Lyra et al., 2009) (Table 7). Th us, 
the proportions of intestinal bacteria may 
refl ect the nature of the microbial interactions 
in the gut and could thus be even more sig-
nifi cant in IBS than the absolute number of 
certain phylotypes.
A weaker negative association was 
observed for Bifi dobacterium spp., C. aerofa-
ciens–like, C. eutactus 97%, D. desulfuricans 
–group, Lactobacillus spp., Veillonella spp. and 
the bowel symptoms or symptom group scores 
in PCA visualisation (Figure 1A and B in 
study III). All these except for Veillonella spp., 
which have been detected in highest quantities 
among IBS-C patients, have previously been 
decreased in IBS-D patients in comparison 
to other IBS symptom subtypes and healthy 
control subjects (Kassinen et al., 2007; Lyra 
et al., 2009) (Table 7). Th e patients were not 
grouped according to the main bowel habit in 
study III. However, they were mostly suff er-
ing from IBS-D and IBS-M (Atte von Wright, 
personal communication). Very recently, the 
abundance of Bifi dobacteria has been shown 
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to be negatively associated with pain in 
healthy individuals (Jalanka-Tuovinen et al., 
2011) as well as with intestinal symptoms in 
IBS patiens (Rajilić-Stojanović et al., 2011).
5.3.2  Microbiota and body mass 
index (BMI)
The average BMI (26.3) of the participants 
indicated mild overweight and thus the partic-
ipants were divided to two groups, under and 
above a BMI of 25, for further analysis. Th e 
group with a BMI over 25 had more Bifi dobac-
terium spp. (P = 0.009) and nearly statistically 
signifi cantly less Lactobacillus spp. (P = 0.060), 
and also reported more systemic symptoms 
than the normal weight subjects (Table 5 in 
study III). Higher counts of Bifi dobacteria spp. 
have also been observed in another study with 
overweight subjects (Turnbaugh et al., 2009). 
Furthermore, an energy restricted diet was 
found to reduce the number of Bifi dobacte-
rium longum and Bifi dobacterium adolescentis 
and increase that of Lactobacillus group (San-
tacruz et al., 2009). Species-specific assays 
could thus have revealed more specifi c altera-
tions in the context of overweight and bifi do-
bacteria, although this was not originally an 
aim of the study.
Earlier, a reduced prevalence and abun-
dance of the Collinsella aerofaciens phylo-
type was shown in IBS patients compared to 
healthy subjects, as well as an increase in the 
prevalence and count of R. torques 94% (Kas-
si nen et al., 2007; Lyra et al., 2009) (Table 7). 
An interesting fi nding for C.  aerofaciens, in 
addition to the ones discussed in the context 
of a healthy microbiota in study I, was that 
the phylotype was negatively associated with 
R. torques 94% (Figure 1 in study III). Also, 
in a recent study, patients with CD and their 
relatives had more R. torques and less C. aero-
faciens in their faeces than healthy controls 
(Joossens et al., 2011). Furthermore, in this 
study, C. aerofaciens was associated with a 
low blood pressure, low sugar levels, low BMI 
and high numberts of Coprococcus eutactus 
97%. In fact, C. aerofaciens was absent in sub-
jects with a BMI over 30. Increased systemic 
symptoms experienced by overweight subjects 
(BMI > 25) make it diffi  cult to defi ne the role 
of C. aerofaciens in IBS. Recently, a benefi cial 
synbiontic eff ect of prebiotics and probiotics 
on intestinal microbiota and GI symptoms 
in IBS was demonstrated, as the consump-
tion of certain oligosaccharides alone or in 
combination with Bifidobacterium animalis 
DN-173010 increased C. aerofaciens in the gut 
and thereby reduced bloating in patients with 
IBS-C (Veiga et al., 2010). Th is independent 
observation strengthens the putative benefi -
cial role of the C. aerofaciens phylotype in IBS 
symptoms in this study.
5.4  Eff ect of a mul  species 
probio  c interven  on on 
selected GI phylotypes (IV) 
The consumption of certain probiotics has 
been shown to alleviate the symptoms of 
IBS in previous studies, as reviewed in sec-
tion 2.4.3. Th e eff ect of a multispecies probi-
otic supplement on the GI microbiota of IBS 
patients was assessed in a placebo-controlled 
six-month double-blind study. The supple-
ment, which consisted of Lactobacillus rham-
nosus GG, L. rhamnosus Lc705, Propionibac-
terium freudenreichii ssp. shermanii JS and 
Bifidobacterium breve Bb99, has previously 
been shown to alleviate the GI symptoms in 
IBS, and the cohort has been monitored with 
qPCR, but the targeted microbial groups and 
species were not associated with the amelio-
rating eff ect (Kajander et al., 2005; Kajander 
et al., 2007). The eight targeted phylotypes 
measured in this study have according to pre-
Results and Discussion
39
vious studies diverged between IBS symptom 
subtypes and healthy individuals (Kassinen et 
al., 2007; Lyra et al., 2009) (Table 7), and were 
thus selected for further monitoring in the 
probiotic trial in this study on 42 participants 
(Table 5).
5.4.1  GI Symptoms
At the beginning of the study, when no sup-
plements were taken, the placebo and probi-
otic groups overlapped when visualised with 
PCA, and no clear associations were seen 
between the measured phylotypes and the GI 
symptoms (abdominal pain, borborygmi, dis-
tension, fl atulence) (Figure 1A in study IV). 
Th e analogous GI symptoms in study III with 
those recorded in study IV were pain, bloat-
ing and gas. However, no signifi cant positive 
and negative association between GI symp-
toms and R.torques 94% and the C. aerofaciens 
phylotype, respectively, was seen as in study 
IV. However, during the supplementation 
(combined time points at 3 and 6 months), the 
placebo group shift ed in the direction of GI 
symptoms and the R. torques 94% phylotype. 
Furthermore, the probiotic group and the C. 
thermosuccinogenes 85% and R. torques 93% 
phylotypes shift ed in the opposite direction 
(Figure 1B in study IV). R. torques 94% and 
C. aerofaciens were oriented in opposite direc-
tions at both observation points, which is in 
accordance with study III.
5.4.2  Phylotype altera  ons
Linear model comparisons showed a decrease 
in the quantity of R. torques 94% in the pro-
biotic group (P = 0.02 at 6 months), whereas 
C. thermosuccinogenes 85% was elevated in 
the probiotic group (P = 0.00 and P = 0.02 
at 3 months and 6 months, respectively). 
Th e abundance of R. torques 93% was higher 
in the probiotic group during consumption 
of the probiotic (P = 0.00 and P = 0.00 at 3 
months and 6 months, respectively), but the 
detected alterations were due to a decrease 
in the placebo group (Table 3 and Figure 2 in 
study IV). Th e analyses for probiotic and pla-
cebo eff ects were also performed separately 
for the IBS-D symptom subtype. Th e IBS-C 
and IBS-M consisted of unbalanced and small 
numbers of subjects (11 and 12 respectively), 
and were thus inappropriate for statistical 
analysis as separate groups. Before the con-
sumption of the probiotic supplement, the R. 
torques 94% phylotype was more abundant in 
the placebo group than in the probiotic group 
among IBS-D patients (P = 0.04 at 0 months). 
The level decreased among the probiotic-
consuming IBS-D subjects in 6 months (P = 
0.01 at 6 months). Th e levels of C. thermosuc-
cinogenes 85% phylotype among IBS-D sub-
jects increased throughout the intervention 
in the probiotic-receiving group (P = 0.01 at 
3 months and P = 0.05 at 6 months). R. tor-
ques 93% showed higher levels in the probiotic 
group at the 3-month time point (P = 0.00) 
among IBS-D patients.
Th e fl uctuation in the counts of the phy-
lotypes between time points could be within 
the normal temporal variation of the intestinal 
microbiota, which is especially unstable in IBS 
patients (Maukonen et al., 2006a). Although 
the subjects were also told not to use other 
probiotics during the study, the previous and 
in some cases long-term consumption of pro-
biotics could still have aff ected the microbiota 
of the participants, at least at the beginning of 
the intervention. Participating in a nutrition 
trial could also affect the eating habits and 
thereby the diet of some individuals, which 
would infl uence the microbiota (Louis et al., 
2007). Furthermore, stress, which is common 




 The C. thermosuccinogenes 85% phy-
lotype, which increased with multispecies 
probiotic supplementation in this study, was 
previously more strongly associated with 
IBS-M subjects and healthy controls than 
with patients suff ering from IBS-D (Lyra et 
al., 2009) (Table 7). The phylotype has also 
occurred in other GI microbiota cohorts of 
healthy individuals (Eckburg et al., 2005; Gill 
et al., 2006). Th e R. torques 94% phylotype, 
which decreased following probiotic supple-
mentation, has been detected at higher levels 
in IBS-D subjects than controls (Lyra et al., 
2009) (Table 7), as well as being associated 
with the severity of GI symptoms in study 
III. Thus, these alterations detected during 
the intervention showed a trend towards the 
pattern previously detected in non-IBS con-
trols free of GI symptoms. Th e R. torques 91% 
phylotype has been associated with IBS-D and 
IBS-M and the R. torques 93% phylotype has 
been associated more strongly with healthy 
control subjects than with IBS-M sufferers 
(Lyra et al., 2009) (Table 7). Th e naming of the 
phylotypes R. torques 91%, 93% and 94% is 
somewhat misleading, as they share less than 
genus-level similarities among each other 
according to sequence comparison, and the 
percentage refers to the similarity to the target 
sequence of the species R. torques. Th us, the 
bacterial species detected by the assays may 
have diff erent metabolic and functional roles 
in the gut, as their abundance responded dif-
ferently during the intervention. 
5.4.3 Mucus
Some microbial alterations related to IBS 
may be associated with excess mucus com-
monly present in IBS (Longstreth et al., 2006). 
The putatively mucin-degrading R. torques 
94%, abundant in IBS, could serve as marker 
of the IBS status in the gut. Similar marker-
phylotypes could be found among Entero-
bacteria. For instance, Enterobacteria include 
opportunistic pathogens, such as Pseudomo-
nas aeruginosa which has proteolytic activity 
and is capable of degrading mucin (Aristoteli 
& Willcox, 2003), and has been detected at a 
higher prevalence and abundance in IBS (Ker-
ckhoff s et al., 2010). An excess of degraded 
mucin could result in a vicious circle by mak-
ing the gut an even more favourable environ-
ment for the above-mentioned bacteria to 
grow in, and further imbalancing the micro-
biota and accelerating the degradation of 
mucin layers with a synergistic eff ect. Th is is 
an interesting issue to speculate as activation 
of mucin-producing genes in the gut has been 
observed in IBS (Aerssens et al., 2008). Many 
individual studies with diff erent cohorts and 
methods have reported Gammaproteobacteria 
(Enterobacteria) and Clostridium cluster XIV 
(Ruminococcus torques affi  liation) to be ele-
vated in IBS and IBD (see sections 2.3.3 and 
5.2). Th ere might be an association between 
the impaired GI health and the two groups of 
bacteria.
On the other hand, as discussed in study 
IV, one mechanism of action of the probiot-
ics in this study could be speculated to lead 
to mucus production, as certain probiotics 
promote mucin secretion in vivo (Ohland 
& Macnaughton, 2010). The expression of 
mucus could thus maintain the epithelial bar-
rier by preventing the mucolytic bacteria from 
disrupting the mucus layer and further mak-
ing the gut susceptible to other unfavourable 
bacteria, promoting overall dysbiosis and even 
low grade inflammation. Another potential 
mechanism of action of the probiotic mixture 
could be associated with the production of 
lactic acid, which can disrupt the outer mem-
branes of Gram-negative pathogens such as P. 
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aeruginosa and thus inhibit their growth (Ala-
komi et al., 2000).
The findings of this study support the 
contention that a multispecies probiotic sup-
plementation has a favourable effect on the 
overall GI microbiota of IBS patients, as in a 
study by Kajander et al. (2008). In the studies 
of this thesis the same probiotic strains were 
used, with the exception that Bifi dobacterium 
animalis ssp. Bb12 was used instead of Bifi -
dobacterium breve Bb99 in study IV (origi-
nal intervention published by Kajander et al. 
2005). Th e eff ects of probiotic strains or their 
combinations are unique, and thus a change in 
even one strain of a mixture may alter the out-
come in the alleviation of the symptoms and 




I %G+C profi ling and fractionation prior to cloning and sequencing can reveal a signifi cantly 
larger proportion of bacteria with a high G+C content among the clones recovered compared 
with an unfractionated sample from the human GI tract. Th e order Coriobacteriales within 
the phylum Actinobacteria, in particular, was found to be more abundant than previously 
estimated in conventional sequencing studies. Constant underestimation of the high G+C 
Gram-positive bacteria might lead to misunderstanding of their role in the healthy and dis-
eased gut. Other members within Actinobacteria than bifi dobacteria could be emphasised in 
GI microbiota studies.
II  Signifi cant diff erences were found between 16S rRNA gene clone libraries of IBS-D patients 
and controls constructed from pooled and %G+C-fractionated faecal DNA. Th e overall 
structure of the microbial community of the libraries was similar. However, the microbial 
communities of IBS-D patients were enriched in Firmicutes and Proteobacteria, but reduced 
in the number of Actinobacteria and Bacteroidetes compared to healthy individuals. Sequenc-
es and OTUs affi  liating with the family Lachnospiraceae within the phylum Firmicutes were 
abundant in IBS-D. Individual samples showed a trend of elevated levels of the Gammapro-
teobacteria phylotype in IBS-D samples.
III An association was detected between the presence and abundance of Ruminococcus torques 
94% and bowel symptoms in IBS subjects. Furthermore, the presence of R. torques 94% nega-
tively aff ected the abundance of Coprococcus eutactus 97%, Collinsella aerofaciens-like and 
Clostridium cocleatum 88% phylotypes. Elevated BMI was associated with low levels of the 
Collinsella aerofaciens-like phylotype and Lactobacillus spp. and with high levels of Bifi dobac-
terium spp.
IV Th e multispecies probiotic supplement with Lactobacillus rhamnosus GG, L. rhamnosus 
Lc705, Propionibacterium freudenreichii ssp. shermanii JS and Bifi dobacterium breve Bb99, 
which is capable of alleviating IBS symptoms, shift ed the intestinal microbiota of IBS subjects 
towards that associated with healthy controls. Th e abundance of the R. torques 94% phylo-
type was reduced and that of the Clostridium thermosuccinogenes 85%-like phylotype was 




In community analysis of the GI microbiota, 
methods that do not discriminate high G+C 
bacteria should be used. Such methods, apply-
ing for instance microarray and pyrosequenc-
ing, could be further developed. Th is is espe-
cially the case if IBS is most likely associated 
with dysbiosis of the microbiota rather than 
the effect of a single bacteria species. Such 
approaches would also aid in studying the rel-
ative proportions of diff erent bacterial groups 
and phylotypes in more detail.
Th e symptoms have so far been the only 
criteria for IBS diagnosis. Th e Lachnospiraceae 
family within Firmicutes and phylotypes phy-
logenetically close to Ruminococcus torques 
warrant further studies as putative markers 
and causative agents. Attempts to cultivate R. 
torques 94% are necessary, e.g. for further in 
vitro studies on mucosal degradation, adhe-
sion, metabolic activity, and properties such as 
existence of fl agella in these bacteria. Th e cul-
tivation and study of the role of the Clostrid-
ium thermosuccinogenes 85% -phylotype in 
the healthy gut could also be a research target. 
Furthermore, closer investigation of Gamma-
proteobacteria (Enterobacteria) phylotypes in 
IBS could be interesting, and screening of this 
group in GI samples could be performed with 
other marker genes than 16S rRNA.
The phylotypes that showed interest-
ing associations with IBS were, however, also 
found in healthy subjects, and their presence 
or abundance does not directly indicate IBS. 
Th erefore, it cannot be concluded what is the 
role of these phylotypes in IBS and whether 
they are a cause or rather a consequence of 
altered bowel physiology. Th is does not mean 
that observations of this kind on their pres-
ence or abundance could not form the basis of 
a non-invasive marker of the syndrome in the 
future. Furthermore, assessment of the GI con-
tent in IBS could also be extended from micro-
biota to GI viromes and their dynamics with 
bacteria, as they are less examined inhabitants 
in the gut. Th e IBS-related alterations detected 
in the GI microbiota in this thesis should defi -
nitely be tested and confi rmed with other large 
sample cohorts and extended to mucosal sam-
ples. Especially the IBS-D associated micro-
biota could be a rewarding research target, as 
it is distinguishable in symptoms and microbi-
ota from other symptom subtypes and healthy 
individuals. Also, a more detailed parallel 
study on GI symptoms and microbiota could 
be carried out in order to defi ne more precise 
links between these factors. In the future, IBS 
could potentially be sub-divided also accord-
ing to other criteria than symptoms.
In order to relieve patients suffering 
from the symptoms, which can sometimes 
be severe, use of faecal transplantation in IBS 
could be considered as a treatment option 
(Grehan et al., 2010). Th e method had proven 
efficiency in CDAD, which shares common 
microbiota signs but has clear overgrowth of 
Clostridium diffi  cile as a sign of the dysbiosis 
and a trigger for symptoms (Khoruts et al., 
2010). However, probiotic therapy in IBS is 
more widely acceptable, as it has proven safety 
and is accessible to all. Th e ameliorative eff ect 
on bowel symptoms and the compositional 
normalisation the GI microbiota warrants fur-
ther studies on the mechanisms of action of 
probiotics in IBS. Th is could lead to more tar-
geted probiotic therapy of IBS patients suff er-
ing from diverse symptoms. Furthermore, the 
genera used as probiotics could be diversifi ed 
as our knowledge of the healthy GI microbiota 
is constantly updated, and Collinsella aerofa-
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